Differential role of caspase-8 in hepatocytes and non-parenchymal liver cells in a model of chronic liver injury and progenitor cell activation by Chaudhary, Kunal
  
Differential Role of Caspase-8 in Hepatocytes and Non-Parenchymal Liver 
Cells in a Model of Chronic Liver Injury and Progenitor Cell Activation 
 
 
 
Von der Fakultät für Mathematik, Informatik und Naturwissenschaften 
der RWTH Aachen University zur Erlangung des akademischen Grades 
eines Doktors der Naturwissenschaften genehmigte Dissertation 
  
 
 
 
vorgelegt von 
 
Master of Science 
Kunal Chaudhary 
Kota, Indien 
 
 
 
Berichter: 
Universitätsprofessor Dipl. Ing. Dr. Werner Baumgartner 
Privatdozent Dr. med. Konrad Streetz 
 
 
 
Tag der mündlichen Prüfung: 5. Dezember 2012 
 
 
 
 
Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek online verfügbar 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"It is every man's obligation to put back into the world at least the equivalent of what he takes 
out of it." — Albert Einstein 
 
 
 
 
 
 
 
 
 
 
 
Table of contents 
 i 
Table of contents 
 
1 Introduction …………............................................................................................... 1 
 1.1 Liver - a unique organ .............................................................................................. 1 
  1.1.1 Physiology of the liver ...................................................................................... 1 
  1.1.2 Chronic liver diseases ....................................................................................... 2 
  1.1.3 Pathophysiology of DDC induced liver injury model ...................................... 3 
  1.1.4 Liver regeneration ............................................................................................ 3 
 1.2 Liver progenitor cells biology .................................................................................. 4 
  1.2.1 Liver progenitor cells (LPCs) ........................................................................... 4 
  1.2.2 Characteristics of LPCs .................................................................................... 5 
  1.2.3 Models of LPCs induction ................................................................................ 5 
  1.2.4 LPCs-mediated liver regeneration .................................................................... 5 
  1.2.5 Factors influencing LPCs activation, proliferation and differentiation ............ 6 
  1.2.6 Clinical applications of the LPCs ..................................................................... 8 
 1.3 Apoptosis …………................................................................................................. 8 
  1.3.1 Molecular mechanisms of apoptosis ................................................................ 9 
  1.3.2 Classification of Caspases  ............................................................................... 10 
2 Aim of the study …………...................................................................................... 12 
3 Materials and methods …....................................................................................... 13 
 3.1 Materials …………................................................................................................... 13 
  3.1.1 Chemicals ......................................................................................................... 13 
  3.1.2 Ready to use analytical chemicals and reagents ............................................... 15 
  3.1.3 Kit systems ....................................................................................................... 16 
  3.1.4 Consumables ..................................................................................................... 16 
  3.1.5 Enzymes, inhibitors and activators ................................................................... 18 
  3.1.6 Antibodies ......................................................................................................... 18 
   3.1.6.1 Primary antibodies ..................................................................................... 18 
    3.1.6.1.1 Western blot ....................................................................................... 18 
    3.1.6.1.2 Fluorescence microscopy .................................................................. 18 
    3.1.6.1.3 Flow cytometry (Fluorescent Activated Cell Sorting, FACS) .......... 19 
   3.1.6.2 Secondary antibodies ................................................................................. 19 
    3.1.6.2.1 Western blot ....................................................................................... 19 
    3.1.6.2.2 Fluorescence microscopy .................................................................. 19 
Table of contents 
 ii 
  3.1.7 Primer-sequences .............................................................................................. 19 
   3.1.7.1 Genotyping-primers ................................................................................... 19 
   3.1.7.2 Real-time PCR primers .............................................................................. 20 
  3.1.8 Instruments and equipments ............................................................................. 21 
  3.1.9 Buffer preparation ............................................................................................ 22 
   3.1.9.1 Anesthesia .................................................................................................. 22 
   3.1.9.2 BrdU .......................................................................................................... 22 
   3.1.9.3 Liver cell isolation buffer .......................................................................... 22 
   3.1.9.4 Tail lysis buffer .......................................................................................... 23 
   3.1.9.5 Whole cell protein extraction buffer .......................................................... 23 
   3.1.9.6 Buffers for western blot ............................................................................. 24 
   3.1.9.7 Agarose gel ................................................................................................ 25 
   3.1.9.8 BSA solution (30%) ................................................................................... 25 
   3.1.9.9 HBSS++ ..................................................................................................... 25 
   3.1.9.10 MACS buffer (degassed) ......................................................................... 25 
 3.2 Methods .................................................................................................................... 26 
  3.2.1 Animal experimental models ............................................................................ 26 
   3.2.1.1 Housing and breeding of mice ................................................................... 26 
   3.2.1.2 Used mouse strains .................................................................................... 26 
    3.2.1.2.1 Generation of hepatocyte-specific conditional Caspase-8 knockout 
(Casp8Δhepa) mice …………………………………………………... 
 
26 
    3.2.1.2.2 Generation of mice carrying a ubiquitous deletion of Caspase-8 
(Casp8ΔMx) and their use for a ubiquitous or tissue-specific 
inducible deletion of the Caspase-8 gene ………………………….. 
 
 
27 
  3.2.2 DNA isolation and analysis .............................................................................. 28 
   3.2.2.1 DNA-isolation from tail biopsis .............................................................. 28 
   3.2.2.2 Polymerase chain reaction (PCR) ............................................................ 28 
  3.2.3 Serum preparation ............................................................................................ 29 
  3.2.4 LPCs activation and liver injury model ............................................................ 29 
  3.2.5 Isolation of liver cells ....................................................................................... 30 
   3.2.5.1 Isolation of primary hepatocytes and nonparenchymal cells (NPCs) …… 30 
   3.2.5.2 Enrichment of LPCs by MACS ................................................................. 30 
   3.2.5.3 Enrichment of immune cells ...................................................................... 31 
Table of contents 
 iii 
   3.2.5.4 Isolation of LPCs through gradient ultracentrifugation …………………. 31 
  3.2.6 FACS ................................................................................................................ 32 
   3.2.6.1 FACS analysis for LPCs characterization ................................................. 32 
   3.2.6.2 FACS analysis for immune cells characterization ..................................... 32 
   3.2.6.3 FACS analysis for cell cycle analysis ........................................................ 33 
   3.2.6.4 FACS analysis for apoptosis analysis ........................................................ 33 
  3.2.7 Microscopy  ...................................................................................................... 33 
   3.2.7.1 Histology  .................................................................................................. 33 
   3.2.7.2 Haematoxylin/Eosin (H&E) staining ......................................................... 33 
   3.2.7.3 Immunofluorescence  ................................................................................ 34 
    3.2.7.3.1 BrdU staining ..................................................................................... 34 
    3.2.7.3.2 Terminal Deoxynucleaotidyl Transferase dUTP Nick End Labeling 
(TUNEL) Assay ................................................................................. 
 
35 
  3.2.8 Isolation of nucleic acids .................................................................................. 35 
   3.2.8.1 Isolation of RNA from liver samples ........................................................ 35 
   3.2.8.2 cDNA synthesis ......................................................................................... 36 
   3.2.8.3 Real-time PCR analysis ............................................................................. 37 
  3.2.9 Protein isolation and analysis ........................................................................... 38 
   3.2.9.1 Extraction of whole cell protein from liver tissue, primary hepatocytes, 
LPCs and immune cells for western blot………………………………... 
 
38 
   3.2.9.2 Extraction of whole cell protein from liver tissue for Caspase-3 assay 
with AFC-lysis buffer ............................................................................... 
 
38 
   3.2.9.3 Western blot analysis ................................................................................ 39 
   3.2.9.4 Caspase assay ............................................................................................ 39 
  3.2.10 Cell culture ..................................................................................................... 40 
   3.2.10.1 LPCs culture ............................................................................................ 40 
   3.2.10.2 Treatment of LPCs with intrinsic inducers of apoptosis ………………. 40 
  3.2.11 Transplantation experiments .......................................................................... 40 
   3.2.11.1 Irradiation of mice ................................................................................... 40 
   3.2.11.2 Bone marrow isolation ............................................................................. 40 
   3.2.11.3 Bone marrow transplantation ................................................................... 41 
  3.2.12 Statistical analysis .......................................................................................... 41 
4 Results ........................................................................................................................ 42 
Table of contents 
 iv 
 4.1 Differential role of Caspase-8 in liver cells during chronic liver injury and 
apoptosis ................................................................................................................. 
 
42 
  4.1.1 Cell specific vs. ubiquitous deletion of Caspase-8 leads to a differential 
phenotype in a model of secondary sclerosing cholangitis ............................. 
 
42 
  4.1.2 Ubiquitous deletion of Caspase-8 leads to an extensive progression of liver 
fibrosis ............................................................................................................. 
 
43 
  4.1.3 Conditional Caspase-8 knockout strains are protected against parenchymal 
apoptosis .......................................................................................................... 
 
45 
 4.2 Ubiquitous deletion of Caspase-8 accelerates the onset of liver regeneration in 
mice after DDC treatment ...................................................................................... 
 
47 
  4.2.1 Accelerated proliferation in the liver of Casp8ΔMx mice compared to 
Casp8loxP/loxP and Casp8Δhepa mice after 4w of DDC treatment ....................... 
 
47 
  4.2.2 Deletion of Caspase-8 results in an enhanced LPCs activation after DDC 
treatment .......................................................................................................... 
 
50 
  4.2.3 Characterisation of LPCs through MACS and FACS ………………………..  53 
  4.2.4 Enhanced LPCs proliferation assessed through PI FACS analysis …………..  55 
 4.3 Expansion of LPCs is accompanied by enhanced inflammatory response .............. 56 
  4.3.1 Enhanced inflammatory response and immune cells infiltration in DDC 
treated Casp8ΔMx mice ..................................................................................... 
 
56 
  4.3.2 Apotosis analysis of liver cells through AnnexinV FACS …………………... 58 
  4.3.3 Enhanced mRNA expression of pro-inflammatory cytokines …...................... 59 
 4.4 Caspase-8 knockout bone marrow transplantation (BMT) aggravates liver 
damage after chronic liver injury ........................................................................... 
 
60 
5 Discussion .................................................................................................................. 62 
 5.1 Hepatocyte specific vs. ubiquitous deletion of Caspase-8 leads to a differential 
phenotype in a model of secondary sclerosing cholangitis ……………………… 
 
62 
 5.2 Conditional Caspase-8 knockout mice are protected against parenchymal 
apoptosis ................................................................................................................. 
 
65 
 5.3 Expansion of LPCs in DDC treated Casp8ΔMx mice liver is correlated with an 
enhanced inflammatory response and immune cells infiltration............................. 
 
67 
6 Summary ..................................................................................................................... 70 
7 Zusammenfassung .................................................................................................... 71 
8 References .................................................................................................................. 72 
Table of contents 
 v 
9 Appendix .................................................................................................................... 85 
 9.1 Abbreviations ........................................................................................................... 85 
Eidesstattliche Erklärung .......................................................................................... 90 
Acknowledgement ....................................................................................................... 91 
Publications .................................................................................................................. 92 
Lebenslauf ..................................................................................................................... 93 
 
List of figures 
 vi 
List of figures 
 
1.1 Liver anatomy .................................................................................................... 1 
1.2 Two different cell lineages that contribute to liver regeneration and repair 
after injury ......................................................................................................... 
 
4 
1.3 Origin and fate of LPCs ..................................................................................... 6 
1.4 Diagram depicting the cytokines, growth factors and transcription factors 
involved in the development, proliferation and differentiation of LPCs ……... 
 
7 
1.5 Composition of the death-inducing signaling complexes (DISC) of TNF-R1, 
CD95 and DR4/5 ……………………………………………………………... 
 
9 
1.6 Simplified diagram of Caspase-8 induced apoptosis …………………………. 10 
3.1 Strategy of hepatocyte-specific conditional Caspase-8 knockout (Casp8Δhepa) . 27 
3.2 Strategy of inducible ubiquitous deletion of Caspase-8 (Casp8ΔMx) ................. 27 
3.3 LPCs induction model ....................................................................................... 29 
3.4 Modified two-step in-situ perfusion method ..................................................... 31 
3.5 Gradient centrifugation ...................................................................................... 32 
3.6 Bone marrow isolation and transplantation ....................................................... 41 
4.1 Caspase-8 is differentially involved in DDC-mediated liver injury .................. 43 
4.2 Enhanced progression of liver fibrosis in Casp8ΔMx  mice after 4w of DDC 
treatment ............................................................................................................ 
 
44 
4.3 Enhanced fibrotic gene expression .................................................................... 45 
4.4 Higher apoptosis rate in controls as compared to Casp8ΔMx and Casp8Δhepa 
mice .................................................................................................................... 
 
46 
4.5 Significantly enhanced FasR and FasL mRNA expression in control mice ...... 47 
4.6 Higher proliferative rate in Casp8ΔMx as compared to Casp8Δhepa and controls 
mice .................................................................................................................... 
 
48 
4.7 Significantly enhanced CcnD1, CcnE1 and CcnA2 mRNA expression in 
Casp8ΔMx mice ................................................................................................... 
 
49 
4.8 Western blot analysis of total protein levels ...................................................... 50 
4.9 Deletion of Caspase-8 results in enhanced LPCs activation after DDC-
mediated liver injury in Casp8ΔMx mice ............................................................ 
 
51 
4.10 Gene expression profiling of LPCs .................................................................... 52 
4.11 Characterization of MACS sorted Sca-1+ cells through FACS assessment ...... 53 
4.12 Enhanced LPCs marker expression in Casp8ΔMx mice ...................................... 54 
List of figures 
 vii 
4.13 Enhanced proliferation of LPCs in Casp8ΔMx mice ........................................... 55 
4.14 Characterization of infiltrating inflammatory cells through FACS assessment   57 
4.15 Western blot analysis of total protein level for pro-Caspase-8 (55 kDa) 
expression was performed to monitor Cre-mediated knockout efficiency …… 
 
58 
4.16 Apoptosis analysis in vitro after Jo2 treatement ............................................... 58 
4.17 mRNA expression of pro-inflammatory cytokines ............................................ 59 
4.18 Western blot analysis of total protein level for pSTAT3 and NF-κB 
expression was performed to monitor inflammatory response .......................... 
 
60 
4.19 Casp8ΔMx mice bone marrow transplantation (BMT) aggravates liver damage 
after chronic liver injury .................................................................................... 
 
61 
5.1 Corellation between magnitude of extracellular matrix deposition, 
inflammation and hepatic microenvironment during activation, proliferation 
and survival of LPCs in a hostile environment................................................... 
 
 
65 
5.2 Model of chronic liver injury and LPCs activation............................................ 69 
1. Introduction 
 1 
1 Introduction 
1.1 Liver - a unique organ 
1.1.1 Physiology of the liver 
 Liver is the largest glandular organ in terms of its metabolic, synthesizing and 
detoxifying functions within mammalian body. It performs a plethora of functions in the 
regulation of blood glucose, synthesizes essential proteins, enzymes, carbohydrates, fatty 
acids, vitamins and co-factors for digestion and lipid metabolism, produces albumin, as well 
as prothrombin, fibrinogen, and non-immune α- and β-globulins. Liver serves as a main site 
for detoxification, eliminating a variety of endogenous and exogenous toxic compounds by 
metabolic conversion and bile acid excretion, regulation of ammonia, iron and bicarbonate 
homeostasis.  
 In adult human, liver makes up only 2% of total body weight (1400-1600 g), and is 
comprised of four lobes (Fig. 1.1). In adult mice, liver accounts for approximately 5% of total 
body weight (7-8 g), and is comprised of five lobes.  
 
 
Figure 1.1 Liver anatomy. Diagram depicting the structure of a liver lobule. Each lobule consists of six portal 
triads surrounding a central vein. Each portal triad consists of a portal vein, a branch of the hepatic artery and a 
bile duct.  Adapted from Junqueira and Carniero, 2002 (1). 
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 The liver is composed of different cell types. Those are parenchymal cells or 
hepatocytes, which represent about 80% of hepatic cells. The non-parenchymal cells (NPCs) 
represents the remaining 20% of cells, which include endothelial cell, resident lymphocytes 
including natural killer (NK) cells and natural killer-T (NKT) cells, T-lymphocytes, Kupffer 
cells, and the population of mesenchymal cells, stellate cells, liver myofibroblasts and 
specialized cells like sinusoidal endothelial cells and cholangiocytes and liver progenitor 
cells (LPCs) (2, 3). 
 
1.1.2 Chronic liver diseases 
Correct liver functions are fundamental to human health and loss of these functions 
can be severely compromising. Chronic liver diseases can be caused by any condition that 
leads to gradual degradation and disorganization of the lobular architecture, portal 
hypertension resulting in fibrosis or cirrhosis and can be potentially fatal in cases of chronic 
liver failure. The word cirrhosis comes from the Greek word kirrhos, which means orange 
yellow (Rene Laennec, 1781-1826). Cirrhosis is considered to be irreversible and regarded as 
a possible end stage of many liver diseases and occurs only when a healthy liver tissue 
becomes damaged and is replaced by a scar tissue. The replacement process does not happen 
at once, but takes place over a gradual course of time. The new-scarred tissue prevents the 
regeneration or healing of the liver. The liver will lose the ability to function as the scarred 
tissue spreads. The consequences are portal hypertension, intrahepatic shunting of blood and 
impaired parenchymal function, which affecting protein synthesis, hormone metabolism and 
excretion of bile and bile salts. The most common complications are gastrointestinal 
hemorrhage, ascites, encephalopathy, bacterial infections, renal failure, hepatocellular 
carcinoma and hepatic failure (4, 5).  
The underlying immunological response has usually been acting for months or years 
where inflammation and tissue repairing are in progress simultaneously which leads in the 
end to fibrosis and cirrhosis (6). The main causes of chronic liver disease or cirrhosis are: 
viral causes (hepatitis B (HBV), and C (HCV), or cytomegalovirus, metabolic causes 
(Haemochromatosis or Wilson’s disease), autoimmune response causes (primary biliary 
cirrhosis or primary sclerosing cholangitis), toxin-related causes (alcoholic liver disease 
(ALD), and non-alcoholic steatohepatitis (NASH), auto-immune hepatitis (AIH), primary 
biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) (7, 8). 
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1.1.3 Pathophysiology of DDC induced liver injury model 
3,5-Diethoxycarbonyl-1,4-dihydrocollidine (DDC) is a porphyrinogenic agent and is a 
powerful inducer of ?-aminolaevulinate synthetase, the first and rate-limiting enzyme of the 
haem-biosynthetic pathway, in mouse liver. Chronic feeding of DDC in mice is a well-
established model to study the mechanisms of LPCs activation and proliferation (9).  
 DDC feeding in mice results in disseminated necrosis, apoptotic bodies, ballooning of 
hepatocytes, deposition of brown pigment in macrophages, pigment plugs in the lumina of 
bile ducts, ductular proliferation, ductular reaction, periductal fibrosis, and portal-portal 
septa. This model is associated with significant elevations of serum transaminase, alkaline 
phosphatase, and serum bile acid levels and therefore useful to investigate the mechanisms of 
liver fibrosis and to test novel therapeutic strategies for these diseases (10). Within this model 
the proliferative capacity of hepatocytes is compromised, thus other regenerative mechanisms 
become activated. As a secondary mechanism here the induction of LPCs becomes important 
(3, 11). 
 
1.1.4 Liver regeneration 
One of the unique potentials of the liver is the capacity to restore its constant mass 
and cell function despite acute mechanical, chemical or immune-related injury. Liver 
regeneration and repair during chronic tissue injury is a complex process that is tightly 
controlled by the precise regulation of cell growth and death. Most knowledge about this 
comes to date from studies using the partial hepatectomy model, which is quite unique as it 
enables the synchronous start and shut down of the regenerative response (12). During 
chronic liver injury the situation is more complex, as individual liver cell types proliferate 
asynchronous and differ in their biological behaviour. Compensatory liver regeneration after 
chronic liver injury involves two distinct ways, depending on the nature of the injury and the 
cellular compartments undergoing proliferation. After partial hepatic resection or chemical 
injury, residing hepatocytes within the remaining liver tissue proliferates and restore the liver 
mass (12). Under certain types of severe liver injury the proliferative capacity of hepatocytes 
is impaired activating a potential stem cell compartment located within the intrahepatic 
biliary tree, giving rise to bipotential cells that ultimately differentiate to hepatic or biliary 
epithelial cells (13). These hepatic stem/progenitor cells are referred to by different names 
including ‘LPCs’ and ‘small hepatocyte-like progenitors’ (SHPCs) in rodents (14, 15) and 
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‘intermediate cells’ in humans (16-18). This cell population has been shown to have 
‘bipotential characteristics’ expressing morphological and immunophenotypic features 
typical of both hepatic and biliary epithelial cells. Wilson and Leduc, 1958, were the first to 
describe the activation of this ‘reserve cell compartment’, which in humans is described as 
‘ductular activation’ or ‘progenitor cell activation’ (19). 
 
 
  
 
 
 
 
 
Figure 1.2. Two different cell lineages that contribute to liver regeneration and repair after injury. First 
line of defense in the face of injury is provided by hepatocytes. When hepatocyte renewal is compromised, or 
the liver damage is more severe, this calls upon activation of the second line of defence i.e. activation of 
bipotential stem/progenitor cells in the canal of Hering, located in the intra-hepatic biliary tree that take over the 
burden of regeneration.   
 
1.2 Liver progenitor cells biology  
1.2.1 Liver progenitor cells (LPCs) 
LPCs were first observed and reported by Kinosita et al. (20) in rat livers, exposed to 
the carcinogenic azo dye ‘Butter Yellow’. Morphologically, LPCs are small in size (relative 
to hepatocytes), with a large, ovoid nucleus with high nuclear to cytoplasmic ratio (21). LPCs 
are localized in the canals of Hering (13, 22, 23), the smallest branches of the intrahepatic 
biliary tree that constitute the putative hepatic stem cell niche (15) and proliferate in the 
periportal region of the liver. During LPCs-mediated liver regeneration, they infiltrate into 
the parenchyma along the periportal regions of the liver (24-26).  
 
 
Liver injury 
Canal of Hering: 
Ductular activation 
Bipotential 
hepatoblasts 
1st line of repair 2nd line of repair 
Adult liver 
Self-renewal Self-renewal 
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1.2.2 Characteristics of LPCs 
 The rodent model of DDC results in extensive growth of LPCs that share 
characteristics similar to hematopoietic progenitor cells, such as the receptor for stem cell 
factor (c-kit), and its ligand stem cell factor and Thy-1 (CD90) (rat) and CD34, a marker of 
early hematopoietic progenitor cells, stem cell antigen-1 (Sca-1) (mouse), specific for 
hematopoietic stem cell (HSC) (27-33). LPCs also express different combinations of 
phenotypic markers from both the hepatocyte and biliary lineage such as OV-6, α-fetoprotein 
(AFP), and Cytokeratine 19 (CK19) (9, 25, 34, 35). These cells are considered as a progenitor 
cell types because of their bipotent differentiation capabilities for both hepatocytes and 
biliary epithelial cells (11, 36-38).  
 
1.2.3 Models of LPCs induction  
Different liver injury models are currently used to study biology in rodents, including 
partial hepatectomy (PH) of two-thirds (70%) of the liver (39, 40), feeding a choline-
deficient diet (CDE) supplemented with ethionine (19), feeding N-2-fluorenyl-acetamide 
(2AAF) in combination with PHx, treatment with pyrrolizidine alkaloids in conjunction with 
PHx, 2-AAF, and DDC (13, 41, 42). In these chronic liver injury models, the normal 
regenerative capacity of hepatocyte is blocked (43). A very efficient and extensive murine-
specific model described is LPCs induction and expansion by feeding DDC supplemented 
rodent chow diet (41).  
 
1.2.4. LPCs-mediated liver regeneration 
 Under conditions of chronic liver injury the liver is crippled by hepatocytes 
senescence prolife impairing the intrinsic proliferative and clonogenic capacity of inherent 
hepatocytes resulting in activation of a secondary bipotential amplifying transit compartment 
of extrinsic stem cells (LPCs) with hepatogenic potentials which are chemo-attracted towards 
to the site of liver injury, finding a niche and attempt to rescue the liver (11, 12, 44). Given 
their resistant to the effects of hepatotoxins/carcinogens, LPCs proliferate and migrate 
throughout the damaged liver lobules to replace lost parenchyma during liver regeneration 
(Fig. 1.3). 
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Figure 1.3 Origin and fate of LPCs.  LPCs are bipotential stem cells, originating from the canals of Hering, 
which differentiate to produce cells of either the hepatocytes or biliary epithelia lineage. Under appropriate 
conditions, LPCs also have the capacity to differentiate into pancreatic cells and intestinal metaplasia, and are 
associated with hepatocellular carcinoma (HCC). Figure modified and adapted from Lowes K.N., 2003 (45). 
 
1.2.5 Factors influencing LPCs activation, proliferation and differentiation 
Microenvironment or liver “stem cell niche” collectively formed by the liver cells 
(hepatocytes, cholangiocytes, and progenitor cells), mesenchymal cells (Kupffer cells, 
endothelial cells, hepatic stellate cells) and the liver stroma regulates stem cells (LPCs) 
proliferation, maintenance and cell fate decisions. Another important factor is the intrinsic 
genetic regulation of stem cells (46). Multiple signaling pathways and an extensive number 
of factors such as, the stem cell factor/c-kit system, the interferon-gamma (IFN-γ) network, 
tumour necrosis factor (TNF), TNF-like weak induction of apoptosis (TWEAK) and 
Interleukin-6 (IL-6) (9, 47) have been identified to regulate the proliferation and 
differentiation of rodent LPCs (Fig. 1.4). Other member of the IL-6 family, including 
leukemia inhibitory factor (LIF) and/or oncostatin M (OSM) (48) levels are increased and 
remains elevated during LPCs activation, suggesting their role in the expansion and 
differentiation of the LPCs compartments (49).   
Key role of OSM in the maturation of fetal hepatocytes in vitro and in vivo has 
recently been implicated, pointing to a similar role in the hepatic differentiation of LPCs (50). 
Interferon (IFN-γ) is another inflammatory cytokine considered to play an integral role in 
controlling stem cell-mediated liver regeneration (51-53). In addition, growth factors such as 
Canal of Hering 
in portal region 
Intestinal metaplasia Basophilic hepatocytes 
LPCs 
Hepatocytes 
HCC 
Biliary epithelium 
Pancreas 
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hepatocyte growth factor (HGF), fibroblast growth factor (FGF), transforming growth factor 
(TGF) (54-56) plays an important role in both early and late events in LPCs activation. With 
the exception of IFN-α the inflammatory cytokines are pro-proliferative for LPCs (57).  
LPCs express the receptors TNF-R1, which binds lymphotoxin alpha and TNF-α, as 
well Fn14, the receptor for TWEAK (58). Signaling through both of these receptors activates 
NF-κB, which is mitogenic for LPCs in vitro (59). It was shown that NPCs, such as liver 
resident macrophages and Kupffer cells, are integral for LPCs proliferation, and their 
depletion blunts the LPCs response. Both endothelial cells and stellate cells can enhance 
LPCs growth and differentiation behavior through the production of growth factors including 
HGF, EGF and TGF-α (60). Stellate cells co-proliferate with LPCs and surround the LPCs in 
a cellular network and may also direct the LPCs via direct cell-cell interaction. Inflammatory 
response mediated through resident Kupffer cells, hepatic stellate cells and infiltrating 
inflammatory cells, which secrete chemokines, growth factors and cytokines in response to 
liver injury also supports LPCs proliferation (45, 61).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Diagram depicting the cytokines, growth factors and transcription factors involved in the 
development, proliferation and differentiation of LPCs. Figure modified and adapted from Lowes K.N. 2003 
(45).  
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1.2.6 Clinical applications of the LPCs 
LPCs existence in liver gives rise to debate and expectations regarding its clinical 
applications. With increasing number of patients waiting for liver transplantation with 
relatively lower organ availability, and due to their differentiation potential, LPCs have an 
enormous potential for new therapeutic treatments to a wide range of liver pathological 
conditions ranging from congenital metabolic diseases, end-stage liver cirrhosis, and 
hepatocarcinogenesis. Several obstacles remain to be overcome before the transplantation of 
LPCs can be used clinically. First, the immediate issue is to determine whether the murine 
studies can be translated to the human situation. Second, a major problem is the maintenance 
and expansion of isolated LPCs in an undifferentiated state in ex-vivo prior to transplantation. 
Third, mechanisms and factors governing differentiation of LPCs selectively to hepatocytes 
or cholangiocytes remains major concern and have to be addressed. Lastly understanding the 
mechanism of immune rejection must also be overcome. 
 
1.3 Apoptosis 
The process of programmed cell death (PCD) also termed as apoptosis (a term 
derived from the Greek word describing the falling off leaves from a tree) was classified as a 
morphological entity in a landmark paper by Kerr and coworkers in 1972 (62), who described 
the formation of apoptotic bodies from a cell. Apoptosis is a defined opposing process of 
mitosis and proliferation, which is essential for embryonic morphogenesis and the 
development of multicellular organisms and in the regulation, and maintenance of the cell 
populations (63). Apoptosis is defined as a physiological mechanism, occurring in a temporal 
sequence, which is regulated via distinct signals and signaling pathways (64, 65).   
Two fundamentally different forms of cell death are described, apoptosis is a frequent 
form of programmed cell death, and necrosis is an accidental passive process starting with 
disruption of the cell membrane and a progressive breakdown of ordered cell structures in 
response to violent environmental perturbations such as severe hypoxia/ ischaemia, extremes 
of temperature and mechanical trauma (66).  
Typical morphological change that occurs during apoptosis includes chromatin 
condensation, nuclear fragmentation, condensation of cytoplasm, rounding-up and 
detachment of cells and subsequently formation of apoptotic bodies containing intact 
organelles, as well as portions of the nucleus (67).   
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1.3.1 Molecular mechanisms of apoptosis 
The event of apoptosis can be initiated by a set of cysteine proteases that are activated 
specifically in apoptotic cells, and are part of a large protein family known as the Caspases 
that are highly conserved through evolution (68-71).  
 Caspase are activated through two main pathways (72, 73). The first (“extrinsic 
pathway) begins at the cell surface and involves ligand-induced activation of death receptors, 
such as members of the TNF receptor family: TNF-R1 (Tumor necrosis factor-receptor 1), 
Fas/CD95, TRAIL-R1/DR4 (TNF-related apoptosis-inducing ligand receptor 1/2)/ (death 
receptor 4/5) and TRAIL-R2/DR5 which have death domain (DD) in their cytoplasmic tail 
(Fig. 1.5). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 1.5 Composition of the death-inducing signaling complexes (DISC) of TNF-R1, CD95 and DR4/5. 
TRADD (TNF-R associated death domain), FADD (Fas associated death domain), TRAF2 (TNF-R associated 
factor 2), NF-κB (Nuclear factor kappa B), cFLIP (cellular FLICE inhibitory protein). Adapted from Danial, 
N.N. and Korsmeyer, S.J. 2004 (74). 
 
 Activation of Fas caused by binding of the respective ligand leads to a conformational 
change of the complex and recruits adapter molecule Fas-Associated protein with Death 
Domain (FADD). Then, via its death effector domain (DED) FADD recruits an inactive form 
of pro-Caspase-8 resulting in the formation of a death inducing signaling complex (DISC) 
(75-77). Pro-Caspase-8 gets activated by proteolytic cleavage (78-81) to convert to an active 
form resulting in the initiation of downstream effector Caspase i.e cleaves Caspase-3 leading 
to cell death (Fig. 1.6) (82-85). 
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Figure 1.6 Simplified diagram of Caspase-8 induced apoptosis. Death receptor mediated apoptosis activates 
pro-Caspase-8 to Caspase-8. Activated Caspase-8 then cleaves and activates downstream effetor Caspases such 
as Caspase-1, 3, 6 and 7. Caspase-3 ultimately leads to apoptosis. 
 
 The second (“intrinsic pathway”) involves mitochondrial integration of cellular stress 
signals such as ionizing radiation, heat shock, osmotic stress or chemotherapy, which leads to 
subsequent cleavage of the cytosolic protein Bid (BH3-interacting domain death agonist) to 
its active form tBid through Caspase-8. tBid translocates into the mitochondrial membrane 
causing subsequent release of cytochrome-c into the cytosol, which activates Caspase, 
initiating the formation of the apoptosome formed by apoptotic protease activating factor-1 
(Apaf-1) and Caspase-9 (86) which cleaves and activates pro-Caspase-3, completing the 
cycle of activation as the initiator Caspase-8 (87). Additionally, more pro-Caspase-8 
molecules are cleaved by Caspase-3 releasing a positive feedback loop (88). 
 
1.3.2 Classification of Caspases 
Caspases are synthesized as inactive proenzymes composed of a prodomain and a 
large and small subunit of Caspase catalytic region (CASc), which undergo proteolysis and 
activation by upstream Caspases or auto-cleaved resulting in the separation of the prodomain 
and the two subunits leading to the activation of Caspase (89-93).  
To date 14 members of the Caspase family, which can be subdivided into three 
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categories, have been identified (94, 95). Two sub-groups of Caspase are characterized as 
initiators (Caspase-2, 8, 9 and 10) with long prodomains of more than 90 amino acids. The 
prodomains consist of either a death effector domain (DED) or Caspase recruitment domains 
(CARD), that are also present in adaptor molecules of the DISC such as FADD, RAIDD or 
also Apaf-1 serving as interaction motifs and executioner or effectors (Caspase-3, 6 and 7) in 
the apoptotic signalling pathway (Fig. 1.5). As the inflammatory Caspase, Caspase-1, 4, 5, 
11, 12 and 13 are included in one subfamily. Caspase-14 is a unique Caspase as it belongs to 
neither apoptotic Caspase nor inflammatory Caspase (96).  
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2 Aim of the study 
Liver regeneration and repair is based on cell proliferation and the concomitant 
clearing of injured tissue. Receptor mediated cell death has been defined as an important 
control element of those cellular interactions. Those cell death signals are mediated through 
the activation of a family of proteases, called initiator and effector Caspases. The particular 
role of the initiator Caspase-8 however within the complex process of chronic liver injury has 
not been thoroughly defined yet. Experiments were aimed to characterize the role of receptor 
mediated cell death in individual liver cell populations with special focus on hepatocytes, 
liver progenitor cells and immune cells. Within this study we therefore applied hepatocyte-
specific conditional Caspase-8 knockout (Casp8Δhepa) mice and mice carrying a ubiquitous 
deletion of Caspase-8 (Casp8ΔMx) to investigate tissue specific effects of this Caspase.  
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3 Materials and methods 
3.1. Materials 
3.1.1 Chemicals  
Product  Company, Location 
Acetic acid 100%   AppliChem, Darmstadt 
Acetone J.T. Baker, Deventer 
Agarose   Invitrogen, Karlsruhe 
Ammonium persulfate (APS) Sigma-Aldrich, Steinheim 
Bovine Serum Albumin (BSA)  Sigma-Aldrich, Steinheim 
5-bromo-2-deoxyuridine (BrDU) Sigma-Aldrich, Steinheim 
Bromophenol blue Serva, Heidelberg 
Chloroform Merck, Darmstadt 
Collagenase Type I Worthington, Lakewood  
Collagenase Type IV Worthington, Lakewood 
DEPC-treated water Applied Biosystems, Darmstadt 
Dexamethasone Sigma-Aldrich, Steinheim 
4´,6-Diamidino-2-phenylindole (DAPI)      St.Katharinen Vector Labs, Burlingame 
Diethylether (DTT) J.T. Baker, Deventer 
Dry milk powder AppliChem, Darmstadt 
EDTA (C10H16N2O8)  AppliChem, Darmstadt 
Eosine (C20H8Br4O5) Sigma-Aldrich, Steinheim 
Ethanol (CH3CH2OH) Fishar, Saarbrücken 
Ethidiumbromide (EtBr) Sigma-Aldrich, Steinheim 
Ficoll 400 Sigma-Aldrich, Steinheim 
Formaldehyde 37% Roth, Karlsruhe 
Glucose (C6H12O6) AppliChem, Darmstadt 
Glycin (C2H5NO2) AppliChem, Darmstadt 
Haematoxylin Roth, Karlsruhe 
Hydrochloric acid (HCl) AppliChem, Darmstadt 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) 
Roth, Karlsruhe 
Isopropyl alcohol (2-Propanol, C3H8O) Merck, Darmstadt 
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Ketamin (C13H16CINO) Ceva, Duesseldorf 
Lymphocyte Separation Medium LSM 1077 PAA, Coelbe 
Magnesium chloride (MgCl2) Sigma-Aldrich, Steinheim 
β-Mercaptoethanol, (C2H6OS)  AppliChem, Darmstadt 
Methanol (CH3OH) VWR, Darmstadt 
3-(N-Morpholino) propanesulfonic acid (MOPS) Roth, Karlsruhe 
Nicotinamide Roche, Mannheim 
Nonidet P-40 Sigma-Aldrich, Steinheim 
Nycodenz Axis-Shield, Oslo 
Orange G (C16H10N2Na2O7S2) Roth, Karlsruhe 
Paraformaldehyde Roth, Karlsruhe 
Penicillin/Streptomycin (pen/strep) Biochrom AG, Berlin 
Phenylmethyl sulfonyl fluoride (PMSF) Roth, Karlsruhe 
Polyacrylamide, poly (2-propenamide) Roth, Karlsruhe 
Ponceau Red Sigma-Aldrich, Steinheim 
Potassium chloride (KCl) Merck, Darmstadt 
Salicylic acid (C7H6O3) Sigma-Aldrich, Steinheim 
Sodium-Azide (NaN3) AppliChem, Darmstadt 
Sodium carbonate (Na2CO3) Merck, Darmstadt 
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe 
Sodium fluoride (NaF) Serva, Heidelberg 
Sodium hydrogencarbonate (CHNaO3)  Roth, Karlsruhe 
Sodium orthovanadate (Na3VO4) AppliChem, Darmstadt 
Sucrose (C12H22O11) Merck, Darmstadt 
Tetramethylethylenediamine (TEMED)      Serva, Heidelberg 
Triacetic acid Merck, Darmstadt 
Tris (C4H11NO3) AppliChem, Darmstadt 
Triton X-100 Serva, Heidelberg 
Trypan blue stain (0,4%) Sigma-Aldrich, Steinheim 
Tween 20 (C58H114O26) Sigma-Aldrich, Steinheim 
Xylazine (C12H16N2S) Bernburg AG, Bernburg 
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3.1.2 Ready to use analytical chemicals and reagents 
 Product Company, Location 
Acrylamide solution 30 % Biorad, Munich 
BioRad Protein Assay Biorad, Munich 
Block and Sample Promega, Mannheim 
Complete Mini®   Roche, Mannheim 
Covering solution for cryo sections (Tissue-Tek®)  Sakura, Staufen 
Diaminobenzidine (DAB) Sigma-Aldrich, Steinheim 
Dako Pen  Dako, Hamburg 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
+4500 mg/l Glucose 
+GlutaMAX 
+Pyruvate   
Invitrogen, Karlsruhe 
DMEM F-12  Invitrogen, Karlsruhe 
DNA marker 1 kb plus Ladder®   Invitrogen, Karlsruhe 
Earles Basic Salt Solution (EBSS) with Ca2+ & Mg2+  Gibco/Invitrogen, Karlsruhe 
EBSS without Ca2+ & Mg2+   Gibco/Invitrogen, Karlsruhe 
ECL-Western-Blot-analysis solution®  Pierce/Thermo Scientific, Dreieich 
Ethidiumbromid Invitrogen, Karlsruhe 
Fetal Calf Serum (FCS) PAA, Coelbe 
Gluthathione Agarose   Sigma-Aldrich, Steinheim 
Oligo dT primer   Qiagen, Hilden 
Paraformaldehyde  Roth, Karlsruhe 
Penicillin/Streptomycin (P/S)  Gibco/Invitrogen, Karlsruhe 
Phospho Buffered Saline (PBS) 1x & 10x  PAA, Marburg 
Polyriboinosinic-polyribocytidylic (pIpC) Amersham, Freiburg 
Red Taq Sigma-Aldrich, Steinheim 
Rotiblock   Roth, Karlsruhe 
Rotiphorese 10x SDS Page Roth, Karlsruhe 
SDS Running buffer 10x Roth, Karlsruhe 
Tris-Acetate EDTA Buffer (TAE-Buffer) 50x Gibco/Invitrogen, Karlsruhe 
TAE Buffer 10x   Roth, Karlsruhe 
Trypsin Inhibitor Sigma-Aldrich, Steinheim 
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Vectashield Mounting Medium with Dapi Vector Laboratories, Burlingame 
Williams-E Medium   Gibco/Invitrogen, Karlsruhe 
 
3.1.3 Kit systems 
       Product Company, Location 
Anti-Sca-1 MicroBead Kit (FITC) Miltenyi Biotec GmbH, Berg. Gladbach 
DNeasy Tissue Kit Qiagen, Hilden 
Hot Star Taq Master Mix Kit Qiagen, Hilden 
Omniscript RT PCR Kit   Qiagen, Hilden 
PE Annexin V Apoptosis Detection Kit I BD Pharmingen, Heidelberg 
RNeasy Mini Kit Qiagen, Hilden 
TUNEL Kit Roche, Mannheim 
TUNEL Label Mix   Roche, Mannheim 
 
3.1.4 Consumables 
Product Company, Location 
Adhesive Real-time PCR Seals  ABgene, Epsom 
Beckman Centrifuge tub Beckman Coulter, Krefeld 
Catheter with injection port (Biovalve®20G: 1.0 
x 25 mm)  
Vygon, Swindon 
Cell scrapers BD, Heidelberg 
Cell strainer, 70 µm nylon mesh BD, Heidelberg 
Coated VICRYL* Plus Sutures (8 x 70 cm: 22 
mm ½C)  
Ethicon, Norderstedt 
Cover slips Menzel-Gläser, Braunschweig 
Cryo tubes  Nunc, Langenselbold 
3,5-Diethoxycarbonyl-1,4-dihydrocollidine 
(DDC) 
Sigma-Aldrich, Steinheim 
Disposable needles 18G, 20G, 22G  BD, Heidelberg 
Disposable scalpels sterile  Feather, Osaka 
Disposable weighing boats  Carl Roth, Karlsruhe 
Ethibond™ Excel Polyester sutures (75 cm: 17 Ethicon, Norderstedt 
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mm ½C) 
FACS tube BD, Heidelberg 
Falcon tubes 50 ml  BD, Heidelberg 
General chow for rodents  Altromin, Lage/Lippe 
Glass pasteur pipette  Brand, Wertheim 
Glassware   Schott-Duran, Mainz 
Hand gloves latex  Semperit, Vienna 
Hand gloves nitril  Semperit, Vienna 
Haematocrit cappilaries (75 mm/75 µl)  Hirschmann Laborgeraete, Eeberstadt 
Hybond-N+ (30 cm × 3 m) membranes  Amersham, Freiburg 
Lab-Tek™ Chamber Slides Nunc, Langenselbold 
MACS LS-Columns  Miltenyi Biotec GmbH, Berg. Gladbach 
Millex®GP filter unit (0.45 µm)  Millipore, Ireland 
Nitrocellulose membrane Protran® Whatman, Dassel 
Parafilm   Pechiney Plastic Packaging, Chicago 
Petri dish Sardest, Nuembrecht 
Reaction tubes (0.5-2 ml)  Eppendorf, Hamburg 
Reaction tubes (15 ml, 50 ml)  Sarstedt, Nuembrecht 
Sterile filter Tipps  VWR, Darmstadt 
Sterile pipettes (2-50 ml)  Sarstedt, Nümbrecht 
Super Frost slides Roth, Karlsruhe 
Tissue-Tek® III Uni-Cassette® System Sakura, Staufen 
Tranfer pipette (3.5 ml)  Sardest, Nuembrecht 
Ultracentrifugation polyallomer tubes  Beckman Instruments GmbH, Munich 
Unterpads with absorbent core of 6 cellulose 
layers  
Hartmann, Heidenheim 
8 Vial strips for PCR  Sardest, Nuembrecht 
Well plates (6; 12; 24 wells)  BD Falcon, Heidelberg 
96 Well plates for Protein/ RNA/DNA 
measurement 
Greiner Bio-one, Frickenhausen 
96 Well plates for Real-time PCR StarLAb, Ahrensburg 
X-ray films Amersham, Freiburg 
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3.1.5 Enzymes, inhibitors and activators 
 Product Company, Location 
Collagenase Type IV  Worthington Biochemical, Lakewood 
Complete Mini Protease Inhibitor Roche, Mannheim 
DNase I Roche, Mannheim 
Omniscript RT  Qiagen, Hilden 
Proteinase K  AppliChem, Darmstadt 
RNase-free DNase I Amersham Biosciences, Freiburg 
SYBR® GreenER qPCR SuperMix Invitrogen, Karlsruhe 
Taq DNA-Polymerase und Buffer Roche, Mannheim 
                                                                          
3.1.6 Antibodies 
3.1.6.1 Primary antibodies 
3.1.6.1.1 Western blot 
Product Company, Location 
SMA   Merck Millipore, Schwallbach 
Caspase-8  Enzo Life Sciences, Loerrach 
GAPDH Biogenesis/AbD Serotech, Kidlington 
NF-κB p65 (A) Santa Cruz Biotechnology, Inc., Heidelberg 
p53   Cell Signalling, Danvers 
PCNA Ab-1  Dianova GmbH, Hamburg 
pSTAT3   Cell Signalling, Danvers 
                                       
3.1.6.1.2 Fluorescence microscopy 
Product Company, Location 
anti-CK19 Santa Cruz Biotechnology, Inc., Heidelberg 
anti-Collagen Abcam, Cambridge 
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3.1.6.1.3 Flow cytometry (Fluorescent Activated Cell Sorting, FACS)  
Product Company, Location 
anti-CD11b PerCP eBioscience, Frankfurt 
anti-CD4 APC  eBioscience, Frankfurt 
anti-CD45 PE  BD Pharmingen, Heidelberg 
anti-Sca-1 FITC  Miltenyi Biotec GmbH, Berg. Gladbach 
anti-OC-1, 2, 3 Kindly provided by Prof. M. Grompe, 
University of Oregon, USA 
 
3.1.6.2 Secondary antibodies 
3.1.6.2.1 Western blot 
Product Company, Location 
rabbit anti-goat HRP      Santa Cruz Biotechnology, Inc., Heidelberg 
chicken anti-mouse HRP   Santa Cruz Biotechnology, Inc., Heidelberg 
anti-rabbit HRP Cell Signalling, Danvers 
chicken anti-rat HRP   Santa Cruz Biotechnology, Inc., Heidelberg 
 
3.1.6.2.2 Fluorescence microscopy 
Product Company, Location 
Alexa 488 donkey anti-mouse Invitrogen, Karlsruhe 
Alexa 594 goat anti-rabbit Invitrogen, Karlsruhe 
 
3.1.7 Primer-sequences 
3.1.7.1 Genotyping-primers (all primers are displayed in 5´-3´ direction) 
Target 
Annealing 
Temp. 
Sequence 
Alb-Cre 62°C fwd: CGG GTG AAC GTG CAA AAC AGG CTC 
rev: CTT GCA TGA CCG GTA TTG AAA CTC CAG 
Casp8loxP/loxP 58°C fwd: AAC TTC GGC CGG CCA ATA ACT TCG 
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 rev: AGC AGA AAA ACT TGA AGA AAC TTG 
Casp8 WT 60°C fwd:  CAT ACT GGT TGA GAA CAA GAC CTG G 
rev: GCA GAG GTG ACA AGA GGC CAC TG 
Mx-Cre 59°C fwd: CCA CGA CCA AGT GAC AGC AAT 
rev: TTC GGA TCA TCA GCT ACA CCA 
 
3.1.7.2 Real-time PCR primers (all primers are displayed in 5´-3´direction) 
Target 
Annealing 
Temp. 
Sequence 
CK19 60°C fwd: CGT ACC CCC AAA GGA AGA CA 
rev: TCA GAC CTG CGT CCC TTT TT 
Cyclin A2 59°C fwd: GTG GTG ATT CAA AAC TGC CA 
rev: AGA GTG TGA AGA TGC CCT GG 
Cyclin D1 60°C fwd: AAG CAT GCA CAG ACC TTT GTG G 
rev:  TTC AGG CCT TGC ATC GCA GC 
Cyclin E1 59°C fwd: TCC ACG CAT GCT GAA TTA TC 
rev:  TTG CAA GAC CCA GAT GAA GA 
FAS 
 
60°C fwd: ATG CTG TGG ATC TGG GCT GT 
rev: TCT CCT CTC TTC ATG GCT GG 
FASL 
 
60°C fwd: TGA ATT ACC CAT GTC CCC AG 
rev: AAA CTG ACC CTG GAG GAG CC 
Fn14 
 
60°C Fwd: CTA GTT TCC TGG TCT GGA GAA GAT G 
rev: CCC TCT CCA CCA GTC TCC TCT A 
GAPDH 60°C fwd: TGT TGA AGT CAC AGG AGA CAA CCT 
rev: AAC CTG CCA AGT ATG ATG ACA TCA 
IL-6 60°C fwd: CCG GAG AGG AGA CTT CAC AG 
rev:  TCC ACG ATT TCC CAG AGA AC 
Pro Collagen-1α 60°C fwd: GAA CAG GGT GTT CCT GAG A 
rev: GGA AAC CTC TCT GCG CTC TT 
α-SMA 60°C fwd: ATG AAG CCC AGA GCA AGA GA 
rev: ATG TCG TCC AGT TGG TGA T 
TNF-α 60°C fwd: GAA ACA CAA GAT GCT GGG ACA GT 
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rev:  CAT TCG AGG CTC CAG TGA ATT C 
TWEAK 
 
60°C fwd: CGA GCT ATT GCA GCC CAT TAT 
rev: TCC TGC TTG TGC TCC ATC CT 
 
3.1.8 Instruments and equipments 
Instruments  Company, Location 
Analytical balance  Sartorius, Goettingen 
AxioImager Z1 Microscope Carl Zeiss, Jena 
CAT RM5 mixer Novodirect, Kehl am Rhein 
Cell incubator Haereus BB 6220 Thermo Scientific, Dreieich 
Cell culture bench BSB6A Gelaire Flow Laboratories, Meckenheim 
Cell culture centrifuge Megafuge 1.0R, Heraeus Thermo Scientific, Dreieich 
Cell culture Incubator, Heraeus Thermo Scientific, Dreieich 
Centrifuge 5415D Eppendorf, Hamburg 
Cooling centrifuge 5417R Eppendorf, Hamburg 
Cryostat HM 550 Microm/Thermo Scientific, Dreieich 
Cryotom HM 550 Cryostat Microm/Thermo Scientific, Dreieich 
Deep freezer, -20°C, -80°C Liebherr, Ochsenhausen 
Eppendorf Tabletop 5417 centrifuge Eppendorf, Hamburg 
FACSCanto II flow cytometer  BD, Heidelberg 
Fuji LAS mini 4000  GE Healthcare Europe, Freiburg 
Gel dryer Biometra, Goettingen 
Heraeus-Kendro Megafuge 1.0R  Thermo Scientific, Dreieich 
MilliQ Plus PF Water Purification System Millipore Corporation, Billerica 
Minigel twin gel chamber  Biometra, Goettingen 
Multichannel pipette  Eppendorf, Hamburg 
Multigel gel chamber  Biometra, Goettingen 
NanoDrop; ND-2000c  Peqlab Biotechnologie, Erlangen 
Optima™ L-80XP Ultracentrifuge Beckman Coulter, Krefeld 
Overhead shaker REAX 2  Heidolph, Schwabach 
Perfusion pump Ismatec, Wertheim-Mondfeld 
pH-Meter Beckman 3500 digital Beckman, Munich 
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pH Meter PB-11 Sartorius, Goettingen 
Pipettes                 Eppendorf, Hamburg 
Powersupply PowerPac HC BioRad, Munich 
7300 Real-Time PCR System Applied Biosystems, Darmstadt 
Roller Mixer SRT 9 Stuart, Staffordshire 
SDS PAGE electrophoresis system PerfectBlue 
Twin L 
Peqlab Biotechnologie, Erlangen 
Semi-Dry-blotter MAXI Blotting chamber Carl-Roth GmbH, Karlsruhe 
Shaking incubator Unimax 1010 Heidolph, Schwabach 
Subcell GT gel chamber  Biorad, Munich 
Thermocycler T3000 and Tpersonal Biometra, Goettingen 
Thermomixer 5436 Eppendorf, Hamburg 
Trans-Blot cell Blotting chamber Biorad, Munich 
QuadroMACS™ Separator Miltenyi Biotec GmbH, Berg. Gladbach 
Vortex Genius 3  IKA, Staufen 
 
3.1.9 Buffer preparation 
3.1.9.1 Anesthesia 
Ketamin  450 µl 
NaCl 0.9% 5 ml 
Rompun 50 µl 
 
3.1.9.2BrdU 
5-bromo-2-deoxyuridine (BrdU) solution 300 mg 
NaCl 0.9% 100 ml 
 
3.1.9.3 Liver cell isolation buffer 
Buffers and media Additives Volume 
High glucose DMEM Soybean trypsin inhibitor 0.04 mg/ml 
 Penicillin, Streptomycin  5% 
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 Fetal calf serum (FCS) 5% 
Solution I EBSS without Ca and Mg 50 ml 
 EGTA 100 mM 
Solution II EBSS with Ca and Mg 30 ml 
 Hepes, pH 7.4 10 mM 
Solution III  EBSS with Ca and Mg   50 ml 
 Hepes, pH 7.4 10 mM 
 Collagenase 0.3 mg/ml 
 
3.1.9.4 Tail lysis buffer 
NID buffer Volume Final concentration 
Gelatine type3 10 mg/ml 10 ml 0.1 mg/ml 
KCl 1 M 50 ml 0.05 M 
MgCl2 1 M 2 ml 2 mM 
NP-40 4.5 ml 0.45% 
Tris 1 M 10 ml 0.01 M 
Tween 20 4.5 ml 0.45% 
H2O add 1 l  
 
3.1.9.5 Whole cell protein extraction buffer 
NP40 buffer Volume Final concentration 
Tris HCl 7.5 pH (1 M) 25 ml 50 mM 
NaCl (5 M)   15 ml  150 mM 
Nonidet P-40  2.5 ml 0.5% 
Sodium fluoride 1.05 g 50 mM 
H2O add 500 ml  
Freshly added:   
Sodium vanadate (100 mM) 100 µl 1 mM 
DTT (1 M)   10 µl  1 mM 
PMSF (100 mM) 100 µl 1 mM 
Complete Mini® (Roche)   1 tablet  
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H2O add 10 ml  
 
3.1.9.6 Buffers for western blot 
Ponceau S 
For a 10x stock solution, a solution of 2% Ponceau S, 30% trichloracetic acid and 
30% sulfosalicylic acid in H2O was generated. The solution was stable at room temperature 
for over one year. 1x Ponceau S working solution was diluted in 1% acetic acid. 
 
10x Running buffer Volume Final concentration 
Tris 15. 1 g 25 mM 
Glycine  2 g 192 mM 
SDS 5 g 0.5% 
dH2O add 1 l  
 
10x Transfer buffer Volume Final concentration 
Tris 24.4 g  
Glycine 112.6 g  
dH2O add 1 l  
For 1x transfer buffer:   
10x transfer buffer 100 ml 10% 
Methanol 200 ml 20% 
dH2O add 1 l  
 
Buffer A Volume Buffer B Volume 
Tris 91.0 g Tris 30.3 g 
SDS 2 g SDS 2 g 
dH2O add 500 ml H2O add 500 ml 
adjust to pH 8.8 (6 M HCl)  adjust to pH 6.8 (6 M HCl)  
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Separating gel 8% 10%   12.5%    15% 
dH2O 21.84 ml 18.5 ml 14.32 ml 10.145 ml 
Buffer A 14.8 ml 14.8 ml  14.8 ml 14.8 ml 
Acrylamide 13.36 ml 16.7 ml 20.87 ml 25.045 ml 
APS 10% 300 µl 300 µl 300 µl 300 µl 
TEMED 30 µl 30 µl 30 µl 30 µl 
 
Stacking gel Volume 
dH2O 18 ml 
Buffer B 7.5 ml 
Acrylamide 4.5 ml 
APS 10% 225 µl 
TEMED 15 µl 
 
3.1.9.7 Agarose gel  
Agarose   1%  
Ethidium Bromide 0.00017% 
in 1x TAE  
 
3.1.9.8 BSA solution (30%)  
BSA  30 g 
PBS In 100 ml 
 
3.1.9.9 HBSS++  
BSA  0.06% 
EDTA in HBSS 0.3 mM 
 
3.1.9.10 MACS buffer (degassed)  
BSA  1.6% 
EDTA 100 mM 
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3.2 Methods 
3.2.1 Animal experimental models 
3.2.1.1 Housing and breeding of mice  
All mice strains were group-housed (3 to 5 per cage) and bred in a pathogen-free, 
temperature and humidity controlled facility at the Institute for Laboratory Animal Science 
(ILAS), University Hospital Aachen with 12 h light-dark cycles and ad libitum access to 
water and pelleted roden chow. All experimental protocols were approved by the local 
authority for environment conservation and consumer protection of the state North Rhine–
Westphalia (LANUV) and the ILAS guidelines and were performed in accordance with the 
German legislation on protection of animals and the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals.  
 
3.2.1.2 Used mouse strains 
To reveal Caspase-8 signalling in LPCs induction and proliferation in DDC induced 
chronic liver injury, we used hepatocyte-specific conditional Caspase-8 knockout 
(Casp8Δhepa) mice (97) and mice with ubiquitous deletion of Caspase-8 (Casp8ΔMx) and Cre   
(-)  (Casp8loxP/loxP) littermates as wild-type (WT) controls. 
 
3.2.1.2.1 Generation of hepatocyte-specific conditional Caspase-8 knockout (Casp8Δhepa) 
mice 
Generation of Casp8Δhepa mice was achieved by crossing transgenic mice that express 
the Cre-recombinase open reading frame (ORF) under the control of both the mouse albumin 
regulatory elements and the α-fetoprotein enhancers (AlfpCre transgene) (98) with mice 
expressing loxP-flanked Caspase-8 alleles (Casp8loxP/loxP)  (Fig. 3.1). 
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Figure 3.1 Strategy of hepatocyte-specific conditional Caspase-8 knockout (Casp8Δhepa). For the 
hepatocyte-specific Caspase-8 deletion, Casp8loxP/loxP mice were crossed with animals expressing a Cre 
transgene under control of the hepatocyte-specific albumin promoter (98). 
 
3.2.1.2.2 Generation of mice carrying a ubiquitous deletion of Caspase-8 (Casp8ΔMx) and 
their use for a ubiquitous or tissue-specific inducible deletion of the Caspase-8 gene 
Generation of Casp8ΔMx mice was achieved by crossing Casp8loxP/loxP mice with 
transgenic mice expressing an Mx-Cre transgene under control of the type-1 Interferon 
(IFN)-sensible myxovirus resistance-1 (Mx-1) promoter (Fig. 3.2) (99).  
 
    
 
 
 
Figure 3.2 Strategy of inducible ubiquitous deletion of Caspase-8 (Casp8ΔMx). For the ubiquitous deletion of 
Caspase-8 (Casp8ΔMx), Casp8loxP/loxP mice were crossed with mice expressing an Mx-Cre transgene under 
control of the type-1 Interferon (IFN)-sensible myxovirus resistance-1 (Mx-1) promoter and transgenic Mx-Cre 
mice were injected i.p. with 20 µg/g body weight pIpC. 
 
To induce deletion of Caspase-8, transgenic Mx-Cre mice were injected 
intraperitoneally (i.p.) with 20 µg/g body weight polyriboinosinic-polyribocytidylic (pIpC) 
(Sigma- Aldrich) three times at 4 d intervals. IFNϒ-induced activation of the Mx1 promoter 
led to the expression of Cre and subsequent deletion of exon 3 and 4 of the Caspase-8. In 
terms of all the parameters tested in this study, the phenotype of the Cre-expressing 
plpC  
20 µg/g 
 
Casp8loxP/loxP 
 
loxP loxP 2 3-4 5 
cre Mx 
Mx-cre 
 
Casp8loxP/loxP 
 
loxP loxP 2 3-4 5 
cre Albumin 
Alb-cre 
 ✕ 
✕ 
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Casp8loxP/loxP mice was indistinguishable from that of wild-type mice, irrespective of the Cre 
strain used. Three weeks after birth, new litters, were separately transferred to new cages and 
sexually subsequently genotyped. 
 
3.2.2 DNA isolation and analysis 
3.2.2.1 DNA isolation from tail biopsis  
Total genomic DNA was isolated from tail biopsis with 200 µl of NID buffer + 1 µl of 
Proteinase K and incubated for 6 h at 56°C with shaking at 800 rpm. After digestion, the 
lysate was incubated at 95°C for 10 min to inactivate the proteinase K, and was spinned 
down at 10,000 rpm for 5 min. The supernatant was transferred to fresh eppendorf tube and 
was used for genotyping PCR. 
 
3.2.2.2 Polymerase chain reaction (PCR) 
Genotyping-PCR was performed with specific primers, standard PCR mastermix, and 
PCR cycling parameters as follows:  
 
Reaction concentration mastermix volume 
Red Taq Master Mix 10 µl  
Primer sense 100 pmol 1 µl 
Primer antisense 100 pmol 1 µl 
H2O 6 µl 
DNA 100 ng 2 µl 
Total 20 µl 
 
 Annealing temperature was calculated individually for each primer set (3.1.7.1) 
according to following formula: 
Tm = 4x (number of G + C) + 2x (number of T + A) – 2°C 
Elongation time was adjusted according to the length of the expected product: 0.5 min/ 500 
bp. 
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PCR cycling parameters: 
Step Temperature Time Cycle 
Melting 98°C   2 min                 35 
Denaturing 95°C      30 s 
Annealing 56°C      60 s 
Elongation 72°C  10 min 1 
Final elongation 72°C  10 min 1 
Conservation 4°C  10 min 1 
 
 Each amplified samples were loaded onto a 1% agarose gel with ethidium bromide 
(EtBr) and the PCR products were separated by applying 120 V for 35 min.  
 
3.2.3 Serum preparation 
Transaminase like alanine-aminotransferase (ALT) is an enzyme catalyzing the 
reversible onversion of α-keto acids to amino acids. This enzyme is qualified as a specific 
marker for liver damage. In this study, mice were first narcotized using isoflorane and 
approximately 500 µl blood samples were collected in serum tube by retro-orbital sinus 
bleeding using glass capillary. Serum was separated from blood by centrifugation at 10,000 
rpm for 10 min and stored in fresh tube at -20°C for determination of aminotransferase 
activities. 
 
3.2.4 LPCs activation and liver injury model 
To induce LPCs activation, 6 to 8w old mice were fed Purina 5015 mouse chow diet 
supplemented with 0.1% wt/wt DDC (Sigma-Aldrich) for 4w (Fig. 3.3) (41). Mice were 
sacrificed at the indicated time points, one portion of liver from each mice were used for 
LPCs isolation and other portion were sampled for histological and RNA analysis.  
 
 
Figure 3.3 LPCs induction model. 
0.1% 3,5-diethoxycarbonyl- 
1,4-dihydrocollide (DDC) diet  
(consistent and massive LPCs activation) 
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3.2.5 Isolation of liver cells 
3.2.5.1 Isolation of primary hepatocytes and nonparenchymal cells (NPCs) 
NPCs and hepatocytes were isolated from mice 4w after DDC feeding using the 
collagenase digestion and differential centrifugation method with slight modification (100). 
Briefly, the liver was perfused with 0.1% collagenase IV (Worthington Biochemical 
Corporation) in EBBS. After perfusion, one of the smaller lobes was surgically removed for 
histological and RNA analysis. Rest of the liver tissue was pelleted into small pieces in 0.1% 
collagenase IV (Worthington) and 0.005% DNase I (Worthington) in EBSS and then 
incubated at 37°C for 40 min with shaking. After digestion, the liver cell suspension was 
filtered through 70 mm mesh (BD) and centrifuged twice at 50 g for 5 min at 4°C, to pellet 
the hepatocytes. The supernatant fraction, which contains NPCs, was then pelleted by 
centrifugation at 500 g for 10 min at 4°C (Fig. 3.4).  
 
3.2.5.2 Enrichment of LPCs by MACS 
LPCs were purified from above obtained NPCs pellet (3.2.5.1). The pellet was 
resuspended in HBSS with 0.1% BSA and 2 mM EDTA and LPCs were isolated using a 
FITC-Sca-1 antibody conjugated to magnetic beads (Miltenyi) and eluted through LS 
columns (Miltenyi) according to the manufacturer´s instructions (Fig. 3.4).  Briefly, for 
isolating LPCs, NPCs pellet (3.2.5.1) was resuspended in 2 ml of MACS buffer. NPCs were 
incubated with FITC-Sca-1 antibody (Miltenyi) with 1:20 ratio to the volume of the blocking 
buffer in which they were resuspended for 10 min at 4°C. After incubation, cells were 
washed with 3 ml of MACS buffer and pelleted. Cell pellet was resuspended in 80 µL of 
buffer per 107 total cells and was incubated with Anti-FITC MicroBeads at 1:40 ratio and 
further incubated for 15 min at 4°C. Cells were washed with MACS buffer and centrifuged at 
1,300 rpm for 10 min at 4°C; the resulting cell pellet was gently resuspended in 2 ml MACS 
buffer gently and applied through calibrated Miltenyi LS columns under a strong magnetic 
field. Columns were washed 3 times with 3 ml of MACS buffer at each step and finally the 
purified cells were collected by positive selection by removing the columns from the 
magnetic field and flushed with MACS buffer. Cell samples were collected for FACS in 
order to check the purity.  
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Figure 3.4 Modified two-step in-situ perfusion method. 
 
3.2.5.3 Enrichment of immune cells  
Sca-1- (flow through) cells from MACS process (Fig. 3.4) were collected for further 
characterization of immune cells. 
 
3.2.5.4 Isolation of LPCs through gradient ultracentrifugation 
Nycodenz was purchased as Nycoprep from Axis.Shield PoC AS (Oslo, Norway).  
Nycodenz stock solution at 30% (wt/v) was prepared using Earle´s basic salt solution (EBSS, 
GIBCO). 26%, 19%, 15%, and 13% solutions were prepared in EBSS by serially diluting the 
stock solution and sequentially layered in an Ultra-Clear centrifuge tube (Beckman, no. 
344059).  Then, the NPCs pellet (3.2.5.1) was resuspended in Nycodenz solution of 11% and 
loaded at the top of the gradient. Centrifugation was set at 8,000 rpm (≈ 8,000 × g) for 40 min 
at 4°C in a Beckman L5-50 Ultracentrifuge with a SW41 Ti swinging rotor, slow 
acceleration, and without brake. After centrifugation, cells were found at the four gradient 
interphases. The cells at each interphase were named F1, F2, F3, and F4, starting with F1 
Isolation of hepatocytes and NPC  
with multiple centrifugation steps 
FACS analysis 
Modified two-step in-situ perfusion method. 
Reagent: HBBS, Collagenase, DNase I 
Sca-1+ cell selection through MACS 
FITC-Sca-1 microbeads kit 
Sca-1- cells Sca-1+ cells 
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(11%-13% interphase) at the top. A 16-gauge needle was used to collect the cells in each 
layer by penetrating the wall of the transparent centrifugation tube. Cells were washed twice 
with HBSS containing 5% FBS and were cultured (Fig. 3.5). It has been reported that phase 
F1 and F2 contains LPCs and phase F3 and F4 contains hepatocytes (13). 
 
 
Figure 3.5 Gradient centrifugation. Five different concentrations of Nycodenz gradient solution, cells are 
resuspended in 11% Nycodenz solution and placed on the top of the gradient. Cell are separated according to 
sizes and densities. 
 
3.2.6 FACS 
3.2.6.1 FACS analysis for LPCs characterization 
 Single cell suspensions of Sca-1+ cells were obtained as above (3.2.5.2) and were 
stained for OC-1, OC-2 and OC-3 for 30 min and subsequently analyzed by FACS (Becton 
Dickinson FACS Canto II).  
 
3.2.6.2 FACS analysis for immune cells characterization 
Dissociated Sca-1- (flow through) liver cells were obtained as described above (Fig. 
3.4), and red blood cells were depleted using BD lysis buffer. After washing, Sca-1- liver 
cells were incubated at 4°C for 30 min in the dark in 100 ml staining medium (HBSS 
containing 30% BSA and 100 mM EDTA) with the following fluorochrome-labeled mAbs 
PE conjugated anti-CD45 Ab, PerCP-conjugated anti-CD11b Ab (eBioscience), and APC 
conjugated anti-CD4 Ab (BD) and were used according to manufacturer’s protocols. Samples 
were then washed and resuspended in staining medium and were analyzed using Becton 
Dickinson FACS Canto II. 7AAD staining was used to label dead cells for exclusion. The 
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mean fluorescence index was calculated using FlowJo software (Treestar, USA). Gating was 
implemented based on negative control staining profiles.  
 
3.2.6.3 FACS analysis for cell cycle analysis 
Hepatocytes, LPCs and immune cells (3.2.5.4) were cultured in 6-well culture plate 
(BD) for 24 h at 37°C. For FACS analysis, cells were trypsinized, centrifuged and washed 
three times in PBS. Cells were incubated in 0.05 mg/ml PI, 0.1% sodium citrate and 0.1% 
Triton X- 100 in the dark overnight at 4°C. After four washes in PBS the cells were sheared 
by aspirating through a needle (0.5623 mm). The samples were analysed with a Becton-
Dickinson FACS Canto II. 
 
3.2.6.4 FACS analysis for apoptosis analysis 
Apoptotic cell death was analysed by double staining with annexinV-FITC and PI, 
where the negative control contained Strep-FITC and Strep-PE to compensate for unspecific 
binding. As annexinV binding buffer (10 mM HEPES/NaOH. pH 7.4, 140 mM NaCl, 2.5 
mM CaCl2), washed once with binding buffer before incubation with annexinV (1 µg/ml) and 
PI (1 µg/ml) in binding buffer. FACS followed routine procedures. Analysis was performed 
with an FACS-Canto II fow cytometer. Cell debris was excluded from analysis by gating. 
 
3.2.7 Microscopy 
3.2.7.1 Histology 
For histological analysis, liver samples were fixed in 4% formalin for 24 h, 
dehydrated, and embedded in paraffin (The above steps of dehydration and paraffin 
embedding was performed at Inter-disicplinary Center for Clinical Research (IZKF) Aachen). 
Sections of 5 µm thickness were cut with an ultra microtome (at a thickness of 1-2 µm) and 
stored at room temperature. 
 
3.2.7.2 Haematoxylin/Eosin (H&E) staining 
To determine the morphological changes, sections were deparaffinized and rehydrated 
by immersing 3 times in Xylol each for 5 min, 100% ethanol (2 x 10 min) 95 % ethanol (2 x 
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10 min), 70% ethanol (2 x 10 min) and 5 min in dH2O twice. Immediately samples were 
immersed in Haemalaun solution, which gave cytoplasm a reddish color for 5 min and then 
rinsed with tap water. Finally sections were incubated with 1% Eosin for 5 min and then with 
70% ethanol for 10 s, 1-3 min with 96% ethanol, 2 x 5 min with 100% ethanol. Finally, the 
samples were immersed 3 times in Xylol. Slices were examined with a Leica bright field 
microscope. Pictures were taken with the DS2MV camera from Nikon and analyzed with 
imaje J imaging software. Data presented in each figure are representative of data obtained 
from at least three separate experiments.  
 
3.2.7.3 Immunofluorescence 
Frozen liver samples embedded in Tissue-Tek were cut in 5 µm thickness sections 
and were fixed for 5 min in -20°C acetone, and air dried for 30 min. For immunofluorescent 
staining, sections were rehydrated in PBS, 0.1% Tween 20, blocked in normal donkey serum 
prepared in 1% BSA in PBS for 1 h to avoid unspecific binding of the antibody. After 
washing with PBS, the sections were incubated with the primary antibodies diluted in PBS 
with 1% mouse serum according to manufacturer’s recommendation  (1:200 - 1:300). 
Antibodies were incubated for 1 h either at room temperature or 4°C over night in a humid 
chamber. After incubation, sections were then washed three times in PBS and incubated with 
a secondary antibody for 1 h at room temperature in the dark. Remaining unbound secondary 
antibody was removed by rinsing the slides three times in PBS for 5 min. DAPI mounting 
medium was applied to the sections for counterstaining of the nuclei. Then slides were 
covered by coverslips and specimens were immediately examined under a fluorescence 
microscope by using appropriate excitation wavelengths depending on the fluorochrome used. 
Pictures were taken with a Zeiss fluorescence microscope using AxioVision 4.6 software 
 
3.2.7.3.1 BrdU staining 
Cell proliferation was detected by BrdU (Sigma-Aldrich) incorporation. Mice were 
injected (i.p.) with 30 µg BrdU /g body weight, dissolved in PBS at 2 h prior to euthanasia. 
Liver samples, frozen in OCT compound (Fischer Scientific) were cut in 5 µm thickness 
sections and BrdU incorporation was examined with a mouse-anti-BrDU antibody in a 1:40 
dilution in PBS /1%BSA over night at 4°C and a secondary antimouse IgG antibody labelled 
with ALEXA488 flourescent dye in a 1:200 dilution in PBS /1%BSA and incubated for 1 h at 
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room temperature. BrdU+ cells were counted in 10 different fields at high (400x) 
magnification, and the percentage of BrdU+ cells was calculated and set into percentage 
relationship to DAPI-nuclei. All of the histological analysis was performed on an 
AxioImager Z1 from Zeiss. 
 
3.2.7.3.2 Terminal Deoxynucleaotidyl Transferase dUTP Nick End Labeling (TUNEL) 
Assay 
Terminal deoxynucleotidyltransferase-mediated nick end labeling (TUNEL) staining 
of deparafinized liver sections was performed using a TUNEL Detection Kit following the 
manufacturer’s instructions (Roche) for detection of apoptosis. In brief, 5 µm thickness of 
frozen liver sections were treated with H2O2, permeabilized for 15 min at 37°C with 
proteinase K (20 µg/ml, Sigma-Aldrich), and then incubated for 1 h at 37°C with a reaction 
mixture containing terminal deoxynucleotidyl transferase (Invitrogen) and biotinylated dUTP 
(Boehringer Ingelheim). Labeled DNA was visualized with an ABC Kit (Vector 
Laboratories) and diaminobenzidine. Nuclei were stained with DAPI using Vectashield 
(Vector Laboratories). The liver sections were mounted on glass slides and fluorescence 
microscopy was performed using a Zeiss fluorescence microscope using AxioVision 4.6 
software. TUNEL+ cells were counted by randomly selecting high-power fields (400x) 
distributed over six independent sections. The numbers of TUNEL+ and TUNEL- cells were 
compiled and the percentages of TUNEL+ cells were calculated. 
 
3.2.8 Isolation of nucleic acids  
3.2.8.1 Isolation of RNA from liver samples 
All work involving RNA was performed using sterile RNase-free single use plastic 
ware. RNase free or DEPC-treated H2O was used. All tools and bench were cleaned with 
RNase Zap before and during usage in order to inactivate RNases. All centrifugation steps 
were conducted at 4°C. Liver samples were taken out of -80°C storage and were cut in small 
piece. This liver piece was mixed with 1 ml of peqGOLD RNA-Pure-solution® in a tube. 
Samples in tube were shredded with an Ultra-Thurax® and incubated for 10 min at room 
temperature. Chloroform (200 µl) was added to each sample and vortexed to ensure proper 
mixing and incubated on ice for 10 min. After incubation, samples were centrifuged at 
15,000 g for 15 min. Three phases were obtained after centrifugation. The upper supernatant 
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phase was pipetted and mixed with an equivalent volume of isopropanol. Samples were 
gently mixed and incubated for 10 min on ice, then pelleted at 15,000 g for 10 min. The 
RNA-pellet was washed twice with 1 ml 70% ice-cold ethanol (5 min at 10,000 rpm), air-
dried and was dissolved in 70 µl 0.1% DEPC water.  
 To determine RNA purity and concentrations by photometer, each sample was diluted 
1:50 in RNase-free dH2O and OD (optical density) was measured at 260 and 280 nm. dH2O 
was used as a blank. A ratio of E260 /E280 between 1.8 and 2.0 accounted for pure RNA. 
 
3.2.8.2 cDNA synthesis 
cDNA or complementary DNA was synthesized from 500 ng total RNA template 
using Omniscript cDNA Kit® from Qiagen according to the manufacturer´s protocol. The RT 
reaction was done as follows: 
 
Reverse transcription protocol 
Step Duration Temperature Number of cycles 
Warm up 10 min 25°C 1 
Reverse transcription 60 min 50°C 1 
Denaturation 5 min 85°C 1 
End step ∞ 4°C - 
 
Component Volume/ reaction 
10x Buffer RT 2 µl 
dNTP mix (5 mM each dNTP) 2 µl 
Oligo-dT primer 10 µM 2 µl 
Omniscript Reverse Transcriptase 1 µl 
Template RNA (1 µg/µl) 2 µl 
dH2O add  20 µl 
 
PCR program Temperature 
60 min  37°C 
5 min 95°C 
cDNA was diluted in dH2O at a ratio of 1:200 and stored at -20°C. 
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3.2.8.3 Real-time PCR analysis 
Real-time quantitative (RT-PCR) was carried out using SybrGreenER quantitative 
polymerase chain reaction Supermix (Invitrogen) on ABI Prism 7700 Thermal Cycler. 
 
PCR reactions in this study were composed as followed: 
Mastermix Volume/ reaction Concentration 
cDNA  5 µl  
Primer sense 0.5 µl 5 pmol 
Primer antisense 0.5 µl 5 pmol 
Sybr green  12.5 µl  
dH2O add 25 µl 
 
The program variations were dependent on the annealing temperature of the used 
primers. Primers for GAPDH were used as loading control, and the level of expression for 
the genes CK19, Cyclin D1 (CcnD1), CcnE1 and CcnA2, collagen-1α, α-SMA, IL-6, TNF-α 
was assessed.  
 
General RT-PCR protocol: 
Step Time [min:s] Temp [°C] Cycle 
Activation 02:00 50  
Denaturation 10:00  95  
Denaturation 00:15 98  
Annealing Tm 00:30  58 40x 
Elongation 00:30 60  
Conservation 00:00 4  
Melting curve 
 
The relative gene expression was calculated according to the 2--ΔΔCt method (101). 
The Ct values of the samples of interest and a control sample were calculated using SDS 
software version 1.3.1 (Applied Biosystems) and the ∆∆Ct values were calculated according 
to the formula: 
∆∆Ct = ∆Ct (sample) - ∆Ct (untreated control) 
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∆Ct (sample) is the Ct value for any sample normalized to endogenous GAPDH 
housekeeping gene expression and ∆Ct (untreated control) is the Ct value for the calibrator 
also normalized to GAPDH. 
From these parameters, the 2--ΔΔ Ct values of all samples were calculated and 
interpreted as fold induction compared to untreated controls. 
 
3.2.9 Protein isolation and analysis 
3.2.9.1 Extraction of whole cell protein from liver tissue, primary hepatocytes, LPCs 
and immune cells for western blot 
Liver tissues were homogenized on ice in NP-40 lysis buffer (3.1.9.5). The 
homogenate was centrifuged at 12,000 rpm at 4°C for 10 min. The protein concentrations 
were determined using a Bradford assay (102) using the following solution: 
 
Bio-Rad Protein Assay solution 200 µl 
Aqua select 798 µl  
1:5 diluted supernatant 2 µl 
The samples were snap frozen in liquid nitrogen and stored at -80°C for further use. 
 
3.2.9.2 Extraction of whole cell protein from liver tissue for Caspase-3 assay with AFC-
lysis buffer 
 For protein extractions, approximately 1 mg of frozen liver tissue was homogenized 
on ice in 500 µl AFC lysis buffer. Homogenate was centrifuged for 10 min at 12,000 rpm and 
4°C. Supernatant was transferred into new tube and concentration was determined. Samples 
were shock frozen in liquid nitrogen and stored at -80°C. 
 
AFC-Lysis Buffer Volume Final concentration 
Hepes 1 M pH 7.4 100 µl 10 mM 
Chaps 10%  100 µl 0.1% 
EDTA 0.5 mM pH 8  40 µl 2 mM 
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DTT 1 M  50 µl 5 mM 
Pefa Block 0.1 M  100 µl 1 mM 
Complete Mini®  1 tablet  
dH2O add 10 ml 
 
3.2.9.3 Western blot analysis 
Fifty micrograms of liver protein was heated for 5 min at 95°C and subjected to SDS/ 
polyacrylamide gel and the separated proteins were electrophoretically transferred to a 
nitrocellulose membrane (PROTRAN©, Whatman) using a western blotting system (BioRad) 
for 2 h at 385 mA. Nonspecific binding was blocked with 5% nonfat dry milk or 5% BSA in 
TBS-T buffer for 1 h at room temperature, and incubated at 4°C over night under gentle 
agitation with primary antibodies at the dilution specified by the manufacturer’s 
recommendations. Following three washes with TBS-T, the membranes were then incubated 
with the horseradish perooxidase (HRP)-conjugated secondary antibody (5% non-fat milk or 
BSA in TBS-T) for 1 h at room temperature under gentle agitation. The membrane was 
washed three times for 10 min with TBS-T and protein bands were visualized with the 
enhanced chemiluminescence (ECL, GE Healthcare Biosciences) for 5 min and then exposed 
to a LAS mini 4000 developing machine (Fuji) until specific signals were detectable. 
GAPDH was used as the loading control. 
 
3.2.9.4 Caspase Assay  
Caspase assay was performed as descrbed earlier (103).One hundred micrograms of 
liver protein lysates were incubated with 20 µM fluorogenic substrates Ac-DEVD-AFC for 
Caspase-3 (BD Pharmingen) activity for 1 h. The fluorescence signals were quantitated using 
a fluorescent plate reader (Packard Instrument Co.) at an excitation wavelength of 360 nm 
and an emission wavelength of 460 nm and the background signals were corrected. The 
Caspase activities were expressed as fold changes over control samples (from corresponding 
wild-type mice). 
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3.2.10 Cell culture 
3.2.10.1 LPCs culture  
LPCs were isolated as described above (3.2.5.4) and washed three times with PBS (15 
min, 13,000 rpm, 4°C). The cell pellet was resuspended in 1 ml culture medium and viability 
was determined with 0.2% trypan blue using a Neubauer hemacytometer. Cells were cultured 
at 37°C in air 5% CO2 in either 6 well cell culture insert companion plate with lid (BD) or 8 
well chambered glass slides (Lab-Tek) at a density of 2 x 106 cells/mL in culture medium 
(DMEM-F12 with 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 10 mM 
Nicotinamide. 1 x 10-7 M Dexamethasone, 2 mM Insulin-Transferrin-Selenium-X, 50 µM ß-
Mercaptehnol) for the first 24 h. After 24 h, 50 ng HGF and 20 ng EGF was added until 
further use. 
 
3.2.10.2 Treatment of LPCs with intrinsic inducers of apoptosis 
The cells in culture were treated with (50 ng/ml) Jo2 antibody (BD Pharmingen) for 
4-6 h. After 6 h, the cells were harvested and were used for FACS apoptosis analysis. A part 
of the cells were used for TUNEL staining (see 3.12.2.1) protocol and were analyzed under 
Zeiss microscope to detect the apoptosis. Also part of cells was used for RNA extraction and 
was used for detection of FAS and FASL ligand mRNA detection through the Real Time 
PCR.  
 
3.2.11 Transplantation experiments 
3.2.11.1 Irradiation of mice 
WT mice were exposed to 12 cGy total body gamma irradiation (Mark I irradiator 
Model 68, J.L. Shepherd) with a 6,000-Ci source administered in 2 doses of 6cGy each, 4 h 
apart. 
 
3.2.11.2 Bone marrow isolation 
Casp8ΔMx mice were were injected intraperitoneally with pIpC dsRNA (5) (20 µg/g 
body weight; Sigma- Aldrich) three times at 4 d intervals. At day 13, bone marrow was 
flushed from the tibia and femur with 5 ml HBSS medium (Gibco-BRL; Invitrogen) 
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containing 2% FCS (Hyclone Laboratories) in 50 ml falcon tube (BD). Cells were filtered 
through a 70 mm cell-strainer, collected by centrifugation at 15,000 rpm for 5 min at 4°C. 
The cells were washed twice in HBSS, resuspended in the same medium, counted, and 
maintained at 4°C until further use.  
 
3.2.11.3 Bone marrow transplantation  
Subsequently, 5 x 107 freshly isolated bone marrow cells (Casp8-/-) were transplanted 
via tail vain injection in WT mice at day 2 (Fig. 3.6). From week 5, these mice were 
subjected to DDC supplemented rodent chow until week 7. At the end of week 7, mice were 
sacrificed for LPCs (3.2.5.2) and immune cells (3.2.5.3) isolation and were analyzed through 
flow cytometry.  
 
 
 
 
 
 
 
 
 
Figure 3.6 Bone marrow isolation and transplantation. 
 
3.2.12 Statistical analysis 
 All numerical datas are expressed as a Mean ± Standard deviation of the mean (sdm) 
and represents at least 4-5 animals per time point. All significant p values were determined 
by unpaired two-tailed Student’s t-test implemented in Excel. Statistical analysis was also 
performed using GraphPad Prism version 5.0 software (GraphPad, La Jolla, CA., USA). A 
value of p<0.05 was considered significant (*p<0.05, **p<0.001, ***p<0.0001). Quantitative 
analysis of BrdU and TUNEL staining was done by analyzing immunohistochemical slides 
with Axiovision software (Zeiss). Quantitative analysis of collagen and CK19 staining from 
immunohistochemical slides was performed via colour-based thresholding using the open 
source software ImageJ. 
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4 Results 
4.1 Differential role of Caspase-8 in liver cells during chronic liver injury and 
apoptosis 
4.1.1 Cell specific vs. ubiquitous deletion of Caspase-8 leads to a differential phenotype 
in a model of secondary sclerosing cholangitis 
The role of receptor mediated apoptosis and Caspase activation during the 
development of sclerosing cholangitis is currently unknown. We thus investigated the role of 
the apical effector Caspase-8 in different liver cell types. Mice with a hepatocyte specific 
deletion of Caspase-8 (Casp8Δhepa) (97) and mice with a ubiquitous deletion of Caspase-8 
(Casp8ΔMx) were applied to a model of DDC induced chronic sclerosing cholangitis. Serum 
transaminases and bilirubin significantly increased in Casp8 WT after DDC treatment as an 
indication for the development of severe cholestatic liver injury. Mice with a hepatocyte 
specific deletion of Caspase-8 (Casp8Δhepa) instead displayed lower ALT and bilirubin levels 
were thus relatively protected from DDC induced injury after 4w of treatment (Fig. 4.1A-B). 
In opposite to this both liver function parameters were significantly stronger elevated in 
Casp8ΔMx mice (Fig. 4.1C-D). 
To better characterize the differential impact of Caspase-8 deletion on liver injury we 
next performed H&E staining of liver sections. Tissue damage and fibrotic remodelling 
became evident at some degree in all animals. In agreement with these findings Casp8ΔMx 
mice displayed more extensive histomorphologic changes including a significantly higher 
number of infiltrating mononuclear cells, a much stronger induction of the DDC-
characteristically periportal cell population as well as increased signs of tissue remodelling 
(Fig. 4.1E-F). 
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Figure 4.1 Caspase-8 is differentially involved in DDC-mediated liver injury. Displayed are serum 
transaminases (ALT) and bilirubin levels in Casp8Δhepa (A-B) and Casp8ΔMx (C-D) after 4w of DDC treatment. 
(E-F) Hematoxylin/Eosin (H&E) staining of liver sections from untreated and DDC treated controls, Casp8Δhepa 
and Casp8ΔMx mice. Results are expressed as mean of at least 4-5 mice per group; error bars indicate SD. *, P < 
0.05; **, P < 0.01.  
 
4.1.2 Ubiquitous deletion of Caspase-8 leads to an extensive progression of liver fibrosis  
Next, fibrosis progression was investigated by performing collagen 
immunohistochemistry with collagen as a marker of fibrosis progression. Morphometric 
quantification of liver tissue from the 4w post DDC treatment time point demonstrated less 
0d W
T hepaΔ
0d C
asp8 4w
 WT h
epaΔ
4w C
asp8
0
2000
4000
6000
*
A
LT
 U
/l
0d W
T hepaΔ
0d C
asp8 4w
 WT h
epaΔ
4w C
asp8
0
10
20
30
40
*
B
ili
ru
bi
n 
U
/l
0d W
T MxΔ
0d C
asp8 4w
 WT
MxΔ
4w C
asp8
0
2000
4000
6000 **
A
LT
 U
/l
0d W
T MxΔ
0d C
asp8 4w
 WT
MxΔ
4w C
asp8
0
10
20
30
40 **
B
ili
ru
bi
n 
U
/l
 
 
 (E) (F)  
 
 
0d 
4w 
Casp8ΔMx WT 
0d 
4w 
Casp8ΔMx WT 
(C) (D)  
(A) (B)  
4. Results 
 
44 
collagen accumulation in Casp8Δhepa mice after 4w of DDC feeding, which again reflects a 
better preservation of liver function within this model (Fig. 4.2A,C). Meanwhile, Casp8ΔMx 
mice dislayed extensive progression of liver fibrosis, as evidenced by collagen staining (Fig. 
4.2B,D).  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.2 Enhanced progression of liver fibrosis in Casp8ΔMx mice after 4w of DDC treatment (A-B) 
Collagen staining of liver tissue derived from livers of Casp8Δhepa, Casp8ΔMx and controls 4w after DDC 
treatment. Representative photomicrographs are shown for each time point (200x magnification). (C-D) 
Graphical analysis of liver collagen staining in Casp8ΔMx mice, Casp8Δhepa and controls 4w after DDC treatment. 
To graphically visualize the difference in collagen fiber accumulation, the intensity of collagen staining in DDC 
treated mice was determined. Photomicrographs of collagen stained slides were analysed using the open source 
ImageJ software (livers from untreated mice were used as controls) *=p<0,05 **=p<0,01. 
 
This finding was further strengthened by an enhanced collagen-1α mRNA (Fig. 4.3A-
B) and α-SMA mRNA (Fig. 4.3C-D) expression in Casp8ΔMx mice compared to Casp8Δhepa 
mice after 4w of DDC treatment.   
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Figure 4.3 Enhanced fibrotic gene expression. (A-B) Collagen-1α and  (C-D) α-SMA mRNA expression was 
quantified by real-time PCR before and 4w after DDC treatment as indicated. RNA was extracted separately 
from individual liver tissues (at least 5 samples/time point were included) at the respective time points, 
*=p<0,05 **=p<0,01. 
 
4.1.3 Conditional Caspase-8 knockout strains are protected against parenchymal 
apoptosis 
In view of the observed differences in injury and inflammation in livers with 
conditional Caspase-8 deficiency after 4w of DDC feeding, we next studied the impact of 
apoptosis in these mice. TUNEL analysis of Casp8Δhepa revealed a reduced number of 
apoptotic cells compared to Casp8 WT mice after 4w of DDC diet (Fig. 4.4A,C). 
Interestingly Casp8ΔMx mice also displayed an overall reduced apoptotic activity, as 
evidenced by determining TUNEL-positivity (Fig. 4.4B,D). Consistently, the activation of 
the downstream effector Caspase-3 was reduced in Casp8Δhepa and Casp8ΔMx mice as well 
(Fig. 4.4E-F) compared to Casp8 WT mice after 4w of DDC diet. 
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Figure 4.4 Higher apoptosis rate in controls as compared to Casp8ΔMx and Casp8Δhepa mice. (A-D) 
Apoptotic cells were analysed by TUNEL staining (green) in livers of Casp8ΔMx, Casp8Δhepa and controls before 
and after DDC treatment as indicated. Representative pictures are shown for each time point. At least 10 view 
fields of 5 livers per time point were included in this analysis. (E-F) Native protein extracts were isolated from 
harvested livers and analyzed in Caspase-3 assays for Caspase-3 substrate turnover. The specific Caspase-3 
activity was determined and calculated as relative unit. Casp3 activity in the controls (untreated mice) was set to 
a relative unit of 1. Each bar represents the mean of at least 4-5 mice per group. *, P < 0.05; **, P < 0.01. 
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47 
These findings were further strengthened by mRNA expression levels of FasR and 
FasL that were concordantly regulated within the four groups with a stronger induction in 
treated control mice as compared to either conditional knockout group (Fig. 4.5A-D).  
 
  
  
Figure 4.5 Significantly enhanced FasR and FasL mRNA expression in control mice. Real-time PCR for 
FasR (A-B) and FasL (C-D) mRNA in Casp8Δhepa, Casp8ΔMx and control mice after 4w of DDC diet treatment 
demonstrates significant basal mRNA expression in DDC treated Casp8 WT livers. The FasR/ GAPDH and 
FasL/GAPDH expression ratio was determined for each time point and calculated as fold induction in 
comparison to untreated controls. Each time point represents the mean of 4-5 mice. *, P < 0.05; **, P < 0.01. 
 
4.2 Ubiquitous deletion of Caspase-8 accelerates the onset of liver regeneration in 
mice after DDC treatment  
4.2.1 Accelerated proliferation in the liver of Casp8ΔMx mice compared to Casp8loxP/loxP 
(Casp8 WT) and Casp8Δhepa mice after 4w of DDC diet treatment 
Hepatic apoptosis is usually counterbalanced by the proliferation of parenchymal or 
stem cells. We thus investigated cellular proliferation as a measure for regenerative 
approaches. While Casp8Δhepa (Fig. 4.6A,C) displayed a reduced overall BrdU-incorporation 
activity, we observed an enhanced proliferation in Casp8ΔMx mice (Fig. 4.6B,D). A further 
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refined analysis in Casp8ΔMx mice unraveled that most of the proliferating cells were located 
within the periportal region (Fig. 4.6E-F), an area known to contain a population of LPCs.  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 4.6 Higher proliferative rates in Casp8ΔMx as compared to Casp8Δhepa and controls mice (A-B) BrdU 
staining of liver sections from Casp8ΔMx, Casp8Δhepa and their respective control mice after 4w of DDC diet 
treatment. Two hours before sacrificing, mice were injected with the nucleotide analogue BrdU. Green: BrdU+ 
nuclei, blue: co-staining total nuclei with DAPI. (C-D) Quantification of total BrdU+ cells relative to total nuclei 
(DAPI) per 200x power field. The amount of BrdU+ nuclei was determined by counting 4 representative high 
power fields/mice after microscopic examination. (E-F) Quantification of BrdU+ hepatocytes and periportal 
cells in Casp8ΔMx mice after 4w of DDC diet. Each value represents the mean of 4-5 mice. *, P < 0.05; **, P < 
0.01. 
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 Corresponding to the counted BrdU incorporation rates we detected a similarly 
regulated gene expression associated with cell proliferation that was further supported by 
elevated levels of Cyclin D1 (Fig. 4.7A-B), E1 (Fig. 4.7C-D) and A2 (Fig. 4.7E-F) mRNA 
expression levels in Casp8ΔMx mice compared to control and Casp8Δhepa mice after 4w of 
DDC treatment.  
 
  
  
  
Figure 4.7 Significantly enhanced CcnD1, CcnE1 and CcnA2 mRNA expression in Casp8ΔMx mice. Real-
time PCR for CcnD1 (A-B), CcnE1 (C-D) and CcnA2 (E-F) mRNA in Casp8Δhepa, Casp8ΔMx and control mice 
after 4w of DDC diet treatment demonstrates significant higher mRNA expression in Casp8ΔMx livers. The 
CcnD1/GAPDH, CcnE1/GAPDH and CcnA2/GAPDH expression ratio was determined for each time point and 
calculated as fold induction in comparison to untreated controls. Each time point represents the mean of 4-5 
mice. *, P < 0.05; **, P < 0.01. 
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This observation could be confirmed at the protein level showing significantly higher 
PCNA expression 4w after DDC in Casp8ΔMx mice compared to Casp8Δhepa and controls (Fig. 
4.8A-B). p53, another cell cycle regulator was regulated in a similar manner as demonstrated 
by western blot analysis (Fig. 4.8C-D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8 Western blot analysis of total protein levels. PCNA (A-B) and p53 (C-D) after 4w of DDC diet 
treatment demonstrating elevated level of proliferation in Casp8ΔMx mice compared to Casp8Δhepa and controls. 
GAPDH (lower panel) was used as internal loading control. 
 
 
4.2.2 Deletion of Caspase-8 results in an enhanced LPCs activation after DDC treatment   
Previous studies have demonstrated that Caspase-8-mediated hepatocyte apoptosis 
plays an important role in liver regeneration (35). However, the role of Caspase-8-mediated 
apoptosis in LPCs activation has not been studied. LPCs are a known major component of 
intrinsic liver regeneration within the DDC model. As the periportal cell fraction was 
enhanced in Casp8ΔMx mice we evaluated their contribution under the condition of Caspase-
8-deficiency. Immunostaining of liver sections showed the presence of large numbers of 
CK19+ cells branching out from portal areas toward the central regions of the liver lobule and 
spanning the liver parenchyma (Fig. 4.9A-B). A quantification of the tissue area covered by 
CK19+ cells revealed a significantly enhanced expansion of this population in the injured 
liver of Casp8ΔMx mice compared to controls and Casp8Δhepa mice after 4w of DDC treatment 
(Fig. 4.9C-D). The latter showed even less CK19+ cells then their controls (Fig. 4.9A,C). This 
finding was further supported by quantitative CK19 mRNA expression analysis that 
demonstrated elevated levels of CK19 expression in the injured liver of Casp8ΔMx mice 
compared to controls and Casp8Δhepa mice after 4w of DDC treatment (Fig. 4.9E-F). 
 
0d WT
 
0d Cas
p8
Δhepa  
4w WT
 
4w Ca
sp8
Δhepa  
(C) (D) 
(A) (B) 
0d WT
 
0d Cas
p8
ΔMx  
4w WT
 
4w Ca
sp8
Mx  
0d WT
 
0d Cas
p8
Δhepa  
4w WT
 
4w Ca
sp8
Δhepa  
0d WT
 
0d Cas
p8
ΔMx  
4w WT
 
4w Ca
sp8
Mx  
PCNA 
GAPDH 
PCNA 
GAPDH 
p53 
GAPDH 
p53 
GAPDH
H 
4. Results 
 
51 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 4.9 Deletion of Caspase-8 results in enhanced LPCs activation after DDC-mediated liver injury in 
Casp8ΔMx mice. (A-B) Immunofluorescence staining for CK19 in liver sections from controls, Casp8Δhepa and 
Casp8ΔMx mice after 4w of DDC diet treatment. (C-D) Graphical analysis of CK19 staining in Casp8ΔMx mice, 
Casp8Δhepa and Casp8loxP/loxP controls 4w after DDC treatment. To graphically visualize the difference in CK19 
accumulation, the intensity of CK19 staining in DDC treated mice was determined. Photomicrographs of CK19 
stained slides were analysed using the open source ImageJ software (livers from untreated mice were used as 
controls). (E-F) Real-time PCR analysis for CK19 mRNA demonstrating significant basal mRNA expression in 
Casp8ΔMx livers. Each time point represents the mean of 4-5 mice. *, P < 0.05; **, P < 0.01. 
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Next, further expression profiles of genes involved in the activation of LPCs were 
undertaken. Analysis of CD133, Fn14 and TWEAK (30, 33) revealed an enhanced 
expression of both factors in Casp8ΔMx mice compared to controls and Casp8Δhepa mice after 
4w of DDC treatment (Fig. 4.10A-F). 
 
  
  
  
Figure 4.10 Gene expression profiling of LPCs. Displayed is quantitative real-time PCR analysis for CD133 
(A-B), Fn14 (C-D) and TWEAK (E-F) mRNAs of controls, Casp8Δhepa and Casp8ΔMx mice after 4w of DDC 
diet treatment. Normalized data are expressed relative to the corresponding value for control mice. mRNA 
expression was quantified by real-time PCR before and 4w after DDC treatment as indicated. RNA was 
extracted separately from individual liver tissues (at least 5 samples/time point were included) at the respective 
time points, *=p<0,05 **=p<0,01. 
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4.2.3 Characterisation of LPCs through MACS and FACS 
 Sca-1 expression on fetal liver stem cell generated in DDC injury models has been 
demonstrated (32). Using FITC-labelled anti-Sca-1 antibody, LPCs were isolated through a 
MACS process and analysed by FACS. We found >98% Sca-1+ cells from the total cell 
fraction with >80% viability through MACS process (Fig. 4.11A-D).  
 
 
 
 
 
 
 
 
 
  
Figure 4.11 Characterization of MACS sorted Sca-1+ cells through FACS assessment. (A-D) 
Representative FACS plots from a MACS-based isolated liver progenitor cell fraction. Cells isolated from 
normal and DDC injured livers were enzymatically dispersed, Sca-1 antibody-labeled, and sorted by MACS. 
Successive gating showed sequential selection of cell-sized events (SSC vs. FSC). Dead cells and debris were 
excluded using 7-AAD labeling and size exclusion, respectively. (C) Sca-1+ displays the gating strategy 
representing % of the total cell fraction (after depleting mature hepatocytes and corresponding to the NPC 
population stained with Sca-1). (E-F) The analysis represents the percentage of the total cell fraction (after 
depleting mature hepatocytes and corresponding to the NPC population stained with Sca-1). *, P < 0.05; **, P < 
0.01. 
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WT mice displayed a strong induction of this fetal liver stem cell marker after DDC 
treatment (Fig. 4.11E). Here again, livers of Casp8ΔMx mice showed a significantly stronger 
activation of LPCs, while Casp8Δhepa livers obviously contained less Sca-1+ cells (Fig. 4.11E-
F).  
Next, we further characterized the isolated LPCs with additional hepatic stem cell 
related markers OC-1 (Fig. 4.12A-B), OC-2 (Fig. 4.12C-D), and OC-3 (Fig. 4.12E-F) (18).  
The co-expression was confirmed by FACS analysis (Fig. 4.12). 
 
  
  
  
Figure 4.12 Enhanced LPCs marker expression in Casp8ΔMx mice. Displayed are representative FACS 
analysis of MACS-based isolations of LPCs fractions, that were labelled and subsequently analyzed for the 
expression of OC-1 (A-B), OC-2 (C-D) and OC-3 (E-F) immediately after isolation. The analysis represents the 
percentage of the total cell fraction (after depleting mature hepatocytes and corresponding to the NPCs 
population stained with Sca-1). *, P < 0.05; **, P < 0.01. 
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4.2.4 Enhanced LPCs proliferation assessed through PI FACS analysis 
To answer the question, whether elevated level of progenitor cells in Casp8ΔMx mice 
are causally related to an enhanced LPCs-proliferation we performed PI-stainings of isolated 
LPCs-fractions (Fig. 4.13).  
 
  
  
 
 
  
 
Figure 4.13 Enhanced proliferation of LPCs in Casp8ΔMx mice. (A-B) Represantative FACS plots of isolated 
LPCs stained with PI. Successive gating showed sequential selection of cell-sized events (SSC vs. FSC). (C-D) 
Dead cells were excluded using size exclusion. (E-F) The fraction of LPCs isolated from WT (left) and 
Casp8ΔMx (right) mice after 4w of DDC diet treatment labelled with PI (50 µg/ml) were gated on single cells. 
Single cells were then marked to calculate different phase of the cell cycle G1, S phase and G2-M. (G) 
Representative flow cytometric analysis of DNA content and cell cycle showing that LPCs sustain elevated rate 
of proliferation potential. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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Here we could demonstrate a significantly stronger PI-uptake in the LPCs-fraction 
isolated from Casp8ΔMx mice (Fig. 4.13A-F), which represents their stronger proliferation. A 
quantification of this staining is given in Fig. 4.13G.  
 
4.3 Expansion of LPCs is accompanied by enhanced inflammatory response 
4.3.1 Enhanced inflammatory response and immune cells infiltration in DDC treated 
Casp8ΔMx mice 
The finding of an increased LPCs induction in livers of Casp8ΔMx mice after DDC 
treatment prompted us to investigate the underlying mechanisms in more detail. We thus 
concentrated in the following mainly on mice with a ubiquitous deletion of Caspase-8 
(Casp8ΔMx), as this group had the strongest ductular-response and LPCs activation. It is 
known, that LPCs proliferation is related to an inflammatory response in the liver (61). FACS 
analysis of livers from Casp8ΔMx mice being treated with DDC for 4w revealed a strong 
increase in infiltrating inflammatory cells compared to Casp8Δhepa and Casp8 WT mice as 
well as compared to control diet fed mice. A dramatic increase in the amount of total 
inflammatory cells (CD45) (Fig. 4.14A-B), macrophages (CD11b) (Fig. 4.14C-D) and T-
lymphocytes (CD4) (Fig. 4.14E-F) was observed in Casp8ΔMx mice.  
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Figure 4.14 Characterization of infiltrating inflammatory cells through FACS assessment. Representative 
flow cytometric plots from a MACS-based isolated Sca-1- cell fraction. Successive gating showed sequential 
selection of cell-sized events (SSC vs. FSC). Dead cells and debris were excluded using 7-AAD labeling and 
size exclusion, respectively. The gate on CD45 (A) represents % of the total immune cell fraction (after 
depleting mature hepatocytes, Sca-1+ cells and corresponding to the NPC population). (A-F) Representative 
FACS analysis showing dramatic increase in the percentage of total inflammatory cells CD45+, macrophages 
CD11b+ and T cells CD4+ in Casp8ΔMx mice compared to control mice. *, P < 0.05; **, P < 0.01. 
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Western blot analysis was thus undertaken, to confirm the efficacy of the Caspase-8 
knockout in different cell populations. This revealed an efficient deletion of Caspase-8 (Fig. 
4.15) in hepatocytes, immune cells and LPCs.  
 
 
 
 
Figure 4.15 Western blot analysis of total protein level for pro-Caspase-8 (55 kDa) expression was 
performed to monitor Cre-mediated knockout efficiency. GAPDH was detected as loading control.  
 
4.3.2 Apotosis analysis of liver cells through AnnexinV FACS 
To proof, that Caspase-8 has a functional effect on cell biology we stimulated freshly 
isolated NPCs from DDC treated Casp8ΔMx and control mice with 50 ng/ml Jo2 antibody in 
vitro. Here we could observe a relative protection from this apoptosis-inducing antibody in 
Casp8ΔMx mice, while NPCs isolated from control mice went into apoptosis (Fig. 4.16A-B). 
 
  
 
  
 
 
 
 
Figure 4.16 Apoptosis analysis in-vitro after Jo2 treatment. (A-B) Representative FACS analysis of the 
apoptotic index of immune cells in a given sample by dual labelling with FITC-labeled AnnexinV (AV) and 
propidium idodide (PI). The different labelling pattern in this assay identifies the different cell subpopulations 
i.e lower right region; apoptotic cell (AV+/PI-), upper left region; necrotic cell (AV+/PI+). *, P < 0.05; **, P < 
0.01; ***, P < 0.001. 
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4.3.3 Enhanced mRNA expression of pro-inflammatory cytokines 
 Next mRNA levels of pro-inflammatory cytokines were determined by RT-PCR 
analysis. Those revealed a higher expression of tumor necrosis factor (TNF-α) mRNA (Fig. 
4.17A-B) and a significant increase of interleukin-6 (IL-6) mRNA in Casp8ΔMx mice 
compared with Casp8Δhepa and controls 4w after DDC diet (Fig. 4.17C-D). Thus the increased 
expression of proinflammatory cytokines in livers of Casp8ΔMx mice after 4w of DDC diet 
correlated with the stronger occurrence of periportal cellular infiltrates.  
 
  
  
Figure 4.17 mRNA expression of pro-inflammatory cytokines. Quantitative real-time PCR analysis for TNF-
α (A-B) mRNA and IL-6 (C-D) mRNA of WT, Casp8Δhepa and Casp8ΔMx mice after 4w of DDC diet treatment. 
Normalized data are expressed relative to the corresponding value for control mice. All data are representative 
of three independent experiments. n = 4-5 *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
 
This observation could be confirmed at the protein level showing significantly higher 
NF-κB and pSTAT3 expression 4w after DDC in Casp8ΔMx mice compared to Casp8Δhepa and 
controls 4w after DDC diet ((Fig. 4.18A-B).  
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Figure 4.18 Western blot analysis of total protein level for pSTAT3 and NF-κB expression was performed 
to monitor inflammatory response. GAPDH was detected as loading control.  
 
4.4 Caspase-8 knockout bone marrow transplantation (BMT) aggravates liver 
damage after chronic liver injury 
So far we could provide evidence that under the condition of ubiquitous Caspase-8-
deletion mice develop enhanced liver injury after DDC treatment. Based on our finding that 
Casp8ΔMx mice displayed significantly more periportal infiltration, inflammation and also 
LPCs induction all culminating in the stronger onset of fibrosis progression we aimed to 
answer the likely question, whether this effect is primarily mediated by BM derived cells. To 
proof this hypothesis we transplanted lethality-irradiated mice with control and Casp8-/- BM. 
Those mice then underwent further DDC treatment. Data from this experiments now first 
showed, that transaminases and bilirubin levels were almost two-fold stronger increased in 
mice having received Casp8-/- BM compared to recipients of control BM (Fig 4.19A-B). 
Second, we were able to proof, that this was correlated with a significant increase in the 
number of infiltrating immune cells. Consistent data were obtained for CD45+, CD11b+ and 
CD4+ cells (Fig. 4.19C-E). Third, we wanted to analyse, whether this was related to an 
enhanced LPCs reaction - in analogy to the experiments using Casp8ΔMx mice (see Fig. 
4.11F). FACS analysis finally confirmed a significantly enhanced number of Sca-1+ cells in 
the Casp8-/- BM-transplanted group (Fig. 4.19F).  
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Figure 4.19 Caspase-8 mice bone marrow transplantation (BMT) aggravates liver damage after chronic 
liver injury. (A-B) Serum transaminases (ALT) and bilirubin levels were almost two-fold stronger increased in 
mice receiving Casp8-/- BM compared to recipients of control BM. (C-E) Representative FACS analysis show a 
significant increase in the percentage of total inflammatory cells CD45, macrophages CD11b and T cells CD4 
in mice receiving Casp8-/- BM compared to recipients of control BM. (F) Representative FACS analysis 
revealed significantly stronger activation of LPCs in mice receiving Casp8-/- BM compared to recipients of 
control BM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
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5 Discussion 
Liver regeneration following chronic injury is controlled through a complex signalling 
network that regulates the balance between cell proliferation and apoptosis (104-106), 
inflammation, the proliferation of LPCs and fibrosis (107). Apoptosis has become the focus 
of many researchers since it became apparent that an imbalance between cell proliferation 
and cell death in the liver contributes to the pathogenesis of several liver diseases (108-112). 
During liver regeneration apoptosis and death-receptor induced cell death are thought to play 
a role in a) the termination of tissue expansion and proliferation and b) to provide space for 
the expanding new cell population. Involved signalling pathways however have not been 
thoroughly defined so far. To address this question hepatocyte-specific knockout mouse 
strains for Caspase-8 (Casp8Δhepa) and mouse strain for a ubiquitous deletion of Caspase-8 
(Casp8ΔMx) were characterized in a model of DDC induced liver injury. We now investigated 
the role of Caspase-8 deletion in different liver cells during chronic liver injury and 
regeneration. 
 
5.1 Hepatocyte specific vs. ubiquitous deletion of Caspase-8 leads to a differential 
phenotype in a model of secondary sclerosing cholangitis  
Caspase-8 is essential for death-receptor mediated apoptosis. The Caspase-8 gene has 
been shown to be indispensable for embryonic development, as constitutive disruption of 
Caspase-8 leads to an impaired heart muscle development and hyperemia. In earlier studies 
the role of receptor-mediated Caspase activation has been investigated through the use of 
newly generated Caspase-8 knockout mice (97). It has been shown that hepatocyte-specific 
deletion of Caspase-8 results in moderate basal liver inflammation and protected mice from 
the induction of apoptosis and liver injury. Interestingly here non-apoptotic liver injury and 
necrosis were increased if the more immune-dependent model of Concanavalin-A (97) 
induced liver injury was used. Further evidence for a tissue protective role of Caspase-8 
comes from data generated in the NEMO-model of liver injury. Cancer development, based 
on a chronic hepatic inflammation due to the failing activation of the transcription factor NF-
κB could be completely abrogated through the simultaneous ablation of NEMO and Caspase-
8 signalling (113). Therefore Caspase inhibition seems to be disease-preventive in certain 
conditions. We thus aimed to define the cell-specific role of Caspase-8 in a relevant mouse 
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model of cholangitis based chronic liver injury that models a number of metabolic and toxic 
liver diseases in mice. 
 To analyse the role of Caspase-8, a hepatocyte-specific knockout mouse strain for 
Caspase-8 (Casp8Δhepa) and a mouse strain for a ubiquitous deletion of Caspase-8 (Casp8ΔMx) 
were subjected to DDC treatment for 4w and analysed for molecular and cellular changes 
during secondary sclerosing cholangitis and liver regeneration compared to appropriate 
control mice (Casp8loxP/loxP).  
 First we could show a clear liver protective effect if the gene was inactivated solely in 
hepatocytes (Casp8Δhepa). Although this might have been somewhat expected, those data 
contain several interesting points. Interestingly transaminases were only reduced by a quarter 
of their original elevation in Casp8Δhepa mice after DDC feeding, but the degree of the 
ductular reaction (Fig. 4.9C, Fig. 4.11E) and fibrosis (Fig. 4.2A,C, Fig.4.3A) were even 
stronger reduced. Thus a greater part of DDC-mediated liver injury is at least partly mediated 
via the activation of hepatocellular death-receptors. Several reports including our own 
previous analysis estimated the number of truly apoptotic cells after DDC feeding in a range 
of 1-3% (114). Although this is a rather moderate number, it is obviously still significantly 
enough to contribute over time to organ failure and to trigger regenerative approaches. Here 
now the possibility remains, that Caspase-8 activates besides Caspases other downstream 
signaling components that are involved in tissue injury, e.g. c-jun N-terminal kinases (JNK) 
(115), the induction of reactive oxygen species (ROS) (116) and BH3-only proteins (117).   
Another likely mechanism, how DDC can harm mouse livers is chemically induced 
injury. Fickert et al. suggested that DDC metabolites change the expression of transporter 
molecules, like bile salt export pumps and multi-drug resistance proteins (118). This in term 
leads to a reduced excretion of glutathione and phospholipids. Subsequently an inflammatory 
response is triggered, which leads to the recruitment and infiltration of neutrophils and other 
inflammatory cells. Through this mechanism liver injury gets perpetuated and remodelling 
occurs. Mice carrying a hepatocyte specific conditional Caspase-8 deletion also showed 
reduced cholestasis (Fig. 4.1B) during DDC treatment. As we do not see remarkable 
differences in the expression of bile-salt transporters, we belive that reduced cholestasis in 
Casp8Δhepa mice is an indirect effect of the preserved function of hepatocytes. However, the 
provided cell protection through the missing activation of the Caspase cascade in Casp8Δhepa 
mice obviously reduces the inflammatory activity in this group.   
Consequently we observed in Casp8Δhepa mice much less periportal cellular infiltration 
and a significantly lower rate of LPCs (Fig. 4.9C and Fig. 4.11E) that are typically induced 
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during DDC treatment under this condition. Biliary epithelial cells most likely are not 
involved here, as Cre-expression is restricted to hepatocytes. This is consistent with some of 
our earlier studies showing an enhanced chronic injury in the DDC model, if hepatocellular 
fitness is impaired (114).  
As a possible consequence of the slowed progression towards chronic injury we see in 
Casp8Δhepa mice now a lower degree of LPCs induction and extracellular matrix 
accumulation. To date it is not fully answered; whether the activation of LPCs follows the 
accumulation of extracellular matrix, or if LPCs themselves might directly or indirectly 
contribute to the activation of matrix producing cells. In a recent report it was convincingly 
shown, that the evolvement of the hepatic stem cell niche and LPCs activation follows 
collagen-accumulation and not the other way around (119). On the other hand Chobert and 
co-wrokers demonstrated that liver fibrosis was not the direct consequences of hepatocellular 
lesions or inflammatory response, but was due to the accumulation of LPCs (120). Further 
analysis by Chobert et. al. showed that CK19+ LPCs expressed fibrogenic cytokine 
transforming growth factor-β (TGF-β), which contributed to the accumulation of α-SMA+ 
myfibroblasts in the ductular reaction leading to enhanced fibrosis. Next, Chobert et. al. 
showed that LPCs did not expressed α-SMA, desmin or fibroblast-specific protein-1, 
demonstrating that LPCs did not undergo an epithelial-mesenchmal transition. Thus futher 
studies have to reveal the exact relationship between LPCs expansion and extracellular 
matrix deposition leading to hepatic fibrosis. 
Accumulating investigations in murine models and chronically diseased human livers 
have also reported a correlation between the presence of extracellular matrix (ECM) 
deposition and magnitude of LPCs expansion (107, 121-127). Van Hul et.al. suggested that in 
addition to the presence of ECM deposition before the expansion of LPCs, LPCs are 
embedded in matrix and that matrix deposition escort the LPCs, paving the way from the 
portal tract to the parenchyma and allowing the progenitor cells to invade the deposited 
matrix. Thus, the established hepatic microenvironment plays an important role in the 
activation, proliferation and survival of LPCs in a hostile environment (Fig. 5.1) (22, 128, 
129). In our study we found a reduced amount of collagen accumulation in Casp8Δhepa mice 
ccompared to WT mice after 4w of DDC feeding as demonstrated by collagen staining in 
Fig.4.2A-B. This finding was further strengthened by a lower collagen-1α mRNA (Fig. 4.3A) 
and α-SMA mRNA (Fig. 4.3B) expression in Casp8Δhepa mice compared to WT mice after 4w 
of DDC treatment, thus supporting the correlation between the importance of ECM 
deposition and the level of LPCs expansion. 
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Figure 5.1 Corellation between magnitude of extracellular matrix deposition, inflammation and hepatic 
microenvironment during activation, proliferation and survival of LPCs in a hostile environment.  
 
Interestingly we observed increased transaminases and bilirubin levels and 
significantly more cholestasis in the Casp8ΔMx mice compared to WT and Casp8Δhepa mice 
after 4w of DDC treatment (Fig. 4.1A-D), thus pointing a different mechanism to be 
responsible in case of a ubiquitous Caspase-8-deletion. We therefore sought after an 
explanation how apoptosis resistance against – Caspase-8-mediated – receptor activated cell 
death in different liver cell types might influence the development of chronic liver injury.  
DDC induced liver damage is accompanied by the induction of a strong intrinsic 
regenerative approach that involves hepatic progenitor cells and a prominent ductular 
reaction. But it also hampers proliferation (41, 118, 130) and comprises metabolic and 
excretory functions of hepatocytes through the down regulation of biliary transporters.  
 
5.2 Conditional Caspase-8 knockout mice are protected against parenchymal 
apoptosis  
Measuring of Caspase-3 activity unravelled that receptor mediated apoptotic activity 
in the liver parenchyma was reduced regardless of the Cre-source, as both Casp8Δhepa and 
Casp8ΔMx mice showed a diminished activity (Fig. 4.4E, F). Thus the observed phenotype 
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must be attributed to other cells then hepatocytes. Here two other cell populations came into 
the focus of our investigations – hepatic progenitor cells and immune cells, as histological 
analysis of Casp8ΔMx mice unravelled their stronger presence in this group after DDC 
treatment. The fact, that Mx-Cre mediated deletion of Caspase-8 however was obviously 
unequivocally quite effective in different tissue compartments (Fig. 4.15) made it further 
likely that Caspase-8 deletion also in NPCs would provoke a diverse phenotype. Both 
immune cells and cells of the LPC compartment displayed enhanced proliferation rates in 
mice with deleted Caspase-8 as compared to their control counterparts.   
Our data point to a significant and so far under recognised role of immune cells in the 
pathogenesis of the DDC model. Indeed isolated immune cells from Casp8ΔMx mice showed 
an intrinsic resistance to apoptosis after Fas-receptor activation through the use of Jo2 
antibody (Fig. 4.16A, B). It is known for long, that defective Fas-signalling - either due to 
defective function of Fas-Ligand or Fas itself - can lead to the development of auto-immune-
lymphoproliferative disorders (131). Mice bearing a defective mutation of the Fas-receptor 
(132) even showed a liver phenotype after reconstitution of BM with Fas-receptor inactive 
cells.  
It has been demonstrated that activated lymphocytes produce a soluble FasL 
homotimer, which is a potent pathologic agent in tissue injury (133). Under normal 
conditions, activation induced cell death (AICD) of mature T cells is regulated by Fas-
mediated AICD, but in certain chronic liver injury (e.g., a viral infection) a strong antigenic 
stimulus could result a defect in this autoregulatory apoptosis inducing mechanism and can 
lead to a deficient activation induced cell death of T lymphocytes. Those in turn over-express 
FasL which results in nonspecific hepatocyte injury and cytotoxicity leading to autoimmune 
effects (132). 
Another proof for our theory of enhanced immune cell activation comes from the 
experiments involving BMT of Caspase-8 deficient donor cells. The apoptosis resistant 
immune cells that repopulate in mice after bone marrow transplantation must act in an auto-
aggressive manner on their host livers. This somehow mimics the above-described auto-
immune-like phenotype that has been reported before for apoptosis resistant immune cells 
(134). Given this as an explanation for the observed phenotype one must demand, that 
inactivation of Caspase-8 in immune cells first provokes them to proliferate and second that 
their activation can cause harm to resident livers. Here it is important to note, that there is no 
obvious spontaneous phenotype and that liver damage must occur first. 	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5.3 Expansion of LPCs in DDC treated Casp8ΔMx mice liver is correlated with an 
enhanced inflammatory response and immune cell infiltration  
It has been shown that liver regeneration following the loss of hepatocytes induced by 
toxins, such as the DDC diet model (13, 30, 118) replication and differentiation of 
intrahepatic progenitor cells occurs. Analysis of the proliferation of LPCs in WT, Casp8Δhepa 
and Casp8ΔMx mice after 4w of DDC treatment as a measure for regenerative approaches, 
displayed stronger proliferation in periportal areas- where LPCs emerge and reside. 
LPCs have been reported to express stem cell antigen (Sca-1) marker, which is also 
expressed on hematopoietic stem cells (135). Petersen et.al. demonstrated Sca-1 expression 
on LPCs using an experimental injury model to induce LPCs proliferation (30). In-depth 
analysis of LPCs demonstrated that a subset of the Sca-1 is positive for stem cell markers 
(e.g. OC-1, OC-2 and OC-3) each of which has been shown tobe important in various LPCs 
studies (32). Consistent with previous reports we also demonstrate Sca-1 (Fig. 4.11A-F), OC-
1, OC-2 and OC-3 (Fig. 4.12A-F) markers expressing LPCs in Casp8ΔMx mice compared to 
WT, Casp8Δhepa and after 4w of DDC treatment.  
 Important parallel pathophysiologic processes between liver inflammation and 
regeneration involving hepatic NPCs (endothelial cells, stellate cells, Kupffer cells and 
lymphoid cells) and hepatocytes during liver regenerative process have been studied (136, 
137). Several inflammatory molecular mechanisms used by cancer cells to proliferate 
effectively may also aply to proliferating liver cells during regeneration, supporting the 
concept that inflammatory mediators are indeed involved in the regulation of regenerative 
process (138, 139). It is known, that LPCs proliferation is related to an inflammatory 
response in the liver (61). Studies have also indicated that DDC diet induced chronic liver 
injury and LPCs proliferation is correlated with increased inflammation (140). We thus 
investigated the inflammation profile in WT, Casp8Δhepa and Casp8ΔMx mice after 4w of DDC 
treatment.  
 It has been shown that TNF-α and IL-6, which are produced by macrophages, play an 
important role in the priming phase of liver regeneration (141, 142). Studies in IL-6-deficient 
(143, 144) and TNF-α receptor 1 (TNF-R1)-deficient (145) mice have shown that liver 
regeneration requires this cytokines. Further, specific studies by inhibiting inflammatory 
cytokines, by treating with dexamethasone or a cyclooxygenase 2-inhibitor, have shown the 
mitogenic potential of inflammatory cytokines for LPCs in the damaged liver (52, 53, 55). 
Based on previous observations suggesting a link between inflammation and the proliferation 
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of LPCs during chronic liver injury, we investigated the effects of an LPCs inducing process 
in a hepatocyte-specific knockout mouse strain for Caspase-8 (Casp8Δhepa) and a mouse strain 
for the ubiquitous deletion of Caspase-8 (Casp8ΔMx) mice. The analysis of the anti-
inflammatory cytokines unrevealed a high expression of interleukin-6 (IL-6) mRNA (Fig. 
4.17C-D) and a significant increase of tumor necrosis factor (TNF-α) mRNA in Casp8ΔMx 
mice compared with Casp8Δhepa and controls 4w after DDC diet (Fig. 4.17A-B). Further flow 
cytometry analysis of immune cells in these mice point to an additionally enhanced 
infiltration of immune cells (CD45, F4/80, CD4) in Casp8ΔMx mice. This finally resulted in a 
stronger fibrosis progression of the underlying sclerosing cholangitis induced by DDC in 
Casp8ΔMx mice, as evidenced by an enhanced expression of collagen-1α and α-SMA. Knight 
and co-workers have demonstrated a correlation between the magnitude of LPCs response 
and the intensity of fibrosis supporting the above results (107).  
 Thus the increased expression of proinflammatory cytokines in livers of Casp8ΔMx 
mice after 4w of DDC diet correlated with the stronger occurrence of periportal cellular 
infiltrates, liver fibrosis and elevated number of LPCs proliferation. 
In summary we demonstrate within the present study, that Caspase-8 has a distinct 
cell specific impact on the function of individual liver cell types in a mouse model of chronic 
cholestatic liver injury and progenitor cell activation. While a hepatocyte specific knockout 
provided protection from liver damage a ubiquitous deletion of Caspase-8 triggered more 
injury and inflammation. This was related to a significantly stronger activation of the LPCs 
compartment and more tissue remodelling. Thus new light is shed on the role of death 
receptor mediated physiological functions in individual cell types, which can lead to 
unexpected consequences upon disturbance. Caspase-inhibition in hepatocytes seems to be a 
promising option to at least temporarily preserve organ function of the whole liver. The 
targeting of Caspase-8 in LPCs can also be a future therapeutic option, as their proliferation 
and thus repopulation potential can be further enhanced through this strategy. However, if 
Caspase-inhibition cannot be securely restricted to the target cell and occurs uncontrolled one 
must be aware of severe side-effects of potential Caspase-8-targeted therapies.  
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Figure 5.2 Model of chronic liver injury and LPCs activation. Hepatocyte specific Caspase-8 knockout 
(Casp8∆hepa) provided protection from liver damage while a ubiquitous deletion of Caspase-8 (Casp8∆Mx) 
triggered more injury and inflammation. Apoptosis is not resposnsible for liver injury in Casp8∆Mx mice. This 
was finally related to a significantly stronger activation of the LPCs compartment and in a stronger fibrosis 
progression of the underlying sclerosing cholangitis induced by DDC in Casp8ΔMx mice, as evidenced by an 
enhanced expression of collagen-1α and α-SMA. 
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Stellate cells 
LPCs 
x 
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6 Summary 
 The balance between apoptosis and proliferation represents the basis for the 
maintenance of tissue homeostasis. Receptor mediated cell death through the activation of 
Caspases has been identified as an important mechanism to control life and death in various 
tissues. In this study, we modulated Caspase-8 activity in individual liver cell types using 
hepatocyte-specific knockout mice for Caspase-8 (Casp8Δhepa) and a mouse strain for a 
ubiquitous deletion of Caspase-8 (Casp8ΔMx) in the DDC (3,5-diethocarbonyl-1,4-
dihydrocollidine) model of secondary sclerosing cholangitis and liver progenitor cells (LPCs) 
activation.  
 Here, we demonstrate that mice with Caspase-8 inhibition in hepatocytes (Casp8Δhepa) 
were protected from DDC-mediated injury, while mice with a ubiquitous conditional 
Caspase-8 knockout (Casp8ΔMx) displayed a significantly enhanced hepatic inflammation and 
tissue injury. This was demonstrated by higher transaminases, bilirubin levels and finally also 
more liver fibrosis. Thereby Caspase-3 activity was reduced in both knockout strains, 
suggesting other mechanisms being responsible for the phenotype. Correlating with enhanced 
liver injury, Casp8ΔMx mice displayed a stronger infiltration of mononuclear immune cells 
and more proliferation of LPCs in periportal areas. Further analysis confirmed that these 
infiltrating immune cells are resistant against extrinsic apoptosis. Bone marrow 
transplantation (BMT) experiments demonstrated that Caspase-8-deficient bone marrow 
derived cells are responsible for increased liver injury in DDC fed mice.   
 Taken together, our in vitro and in vivo finding demonstrates a cell-specific and 
distinct impact of Caspase-8 on individual liver cell types. While a hepatocyte specific 
knockout provided protection from liver damage the ubiquitous deletion of Caspase-8 
triggered more injury and inflammation. This phenotype was associated with a stronger 
ductular reaction and activation of the hepatic progenitor cell niche and caused through 
mechanism of immune-cell mediated liver injury.  
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7 Zusammenfassung 
 Das Zusammenspiel von Apoptose und Zellproliferation bildet die Basis für die 
Aufrechterhaltung der Gewebshomöstase. Der zur Apoptose führende sog. Rezeptor-
vermittelte Zelltod wird durch die Aktivierung von Caspasen ausgelöst und stellt in vielen 
Geweben einen wichtigen Mechanismus für die Kontrolle der Zellfunktion dar. In der hier 
präsentierten Arbeit wurde die Rolle und pathophysiologische Bedeutung von Caspase-8 in 
verschiedenen Leberzelltypen untersucht. Dabei kamen konditionale Caspase-8 Knockout 
Mäuse, die entweder einen Hepatozyten-spezifischen (Casp8Δhepa) oder einen ubiquitären 
(Casp8ΔMx) Knockout aufwiesen zum Einsatz. Untersucht wurden die Mäuse im DDC (3,5-
diethocarbonyl-1,4-dihydrocollidine) vermittelten Modell der sekundär-sklerosierenden 
Cholangitis und Lebervorläuferzell- (LPCs) Induktion.  
 Dabei konnte dargelegt werden, dass Mäuse mit Hepatozyten-spezifischem Caspase-8 
KO im DDC-Modell geschützt waren, während eine ubiquitäre Caspase-8-Deletion zu einer 
vermehrten Leberentzündung und Gewebsschädigung führte. Dies wurde durch Nachweis 
erhöhter Transaminasen, Cholestaseparameter und schliesslich vermehrte Fibroseprogression 
gezeigt. Da die Aktivität der abhängigen Caspase-3 in beiden Mauslinien reduziert war, 
mussten andere Mechanismen für den Phänotyp verantwortlich sein. Korrelierend zur 
vermehrten Schädigung zeigten Casp8ΔMx Mäuse eine stärkere Infiltration mononukleärer 
Zellen und eine vermehrte LPCs Proliferation in periportalen Arealen. Weitere Analysen 
bestätigten, dass diese infiltrierenden Immunzellen resistent gegenüber extrinsischer 
Apoptose nach Fas-Aktivierung waren. Knochenmarktransplantationsexperimente 
demonstrierten dann, dass Mäuse nach Rekonstitution mit Caspase-8-defizientem 
Knochenmark eine vermehrte Leberschädigung nach DDC-Behandlung zeigten. 
 Zusammengefasst demosntrieren die dargelegten Daten, dass ein Fehlen von Caspase-
8 zu Zelltyp-spezifischen distinkten pathophysiologischen Konsequenzen führt. Ein 
hepatozyten-spezifischer Knockout schützt die Leber, während eine ubiquitäre Deletion von 
Caspase-8 zu vermehrter Leberschädigung und Entzündung führt. Dieser Phänotyp war mit 
einer immun-vermittelten vermehrten duktalen Reaktion und der Aktivierung der hepatischen 
Stammzellnische verbunden.  
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9 Appendix 
9.1 Abbreviations 
AA Amino acid 
Ab Antibody 
Alb Albumin 
ALT Alanine transaminase 
as Anti-sense 
AST Aspartate transaminase 
ATP Adenosine triphosphate 
bp Basepair 
BM Bone marrow 
BrdU 5-Bromo-2’-deoxy-uridine 
BSA Bovine Serum Albumin 
Casp Caspase (cysteine aspartate-specific proteinases) 
CCl4 Carbon tetrachloride 
Ccn Cyclin 
CDE Choline-deficient, ethionine 
cDNA Complementary Desoyribonucleic acid 
c-Kit CD117 or c-Kit receptor 
Cre Causes recombination 
Ct Threshold Cycle 
d Day 
DAB Diaminobenzidine 
DAPI 4’,6-Diamidino-2-phenylindole 
dATP Desoxyadenosintriphospate 
DDC 3,5-Diethoxycarbonyl-1,4-dihydro-collidine 
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DEPC Diethyl pyrocarbonate 
dH2O Distillated water 
DMEM Dulbecoo’s Modified Eagle Medium 
DNA Deoxyribonucleic acid 
dNTP Desoxyribonucleosidtriphosphate 
ds Double-stranded 
DTT Dithiotreitol 
dTTP Desoxythmidintriphospate 
EBSS Earles basic salt solution 
ECL Enhanced Chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylene Diamine Tetra-Acetic Acid 
e.g. For example (lat. exempli gratia) 
EGF Epidermal Growth Factor 
et al.  And others 
EtBr Ethidium bromide 
EtOH Ethanol 
FACS Fluorescent Activated Cell Sorting, flow cytometry 
FasL Fas-ligand 
FasR Fas-receptor 
FCS Fetal calf serum 
Fig. Figure 
FITC Fluorescein isothiocyanate 
fwd Forward 
g Gram 
g Acceleration of gravity 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 
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h Hour 
HBSS Hank’s Balanced Salt Solution 
HCC Hepatocellular carcinoma 
H&E Hematoxyline/eosin 
HGF Hepatocyte growth factor 
HRP Horseraddish peroxidase 
IGF Insulin-like growth factor 
IgG Immunoglobulin G 
IL Inerleukin 
i.p. Intraperitoneal 
kDa Kilodalton 
kg Kilogram 
L Liter 
loxP Lipopolysaccharide 
LPCs Liver progenitor cells 
µ Micro 
M Molar 
MACS Magnetic Assorted Cells Sorting 
min Minute 
mg Miligram 
ml Milliliter 
mM Milimolar 
mRNA Messenger Ribonucleic Acid 
Mx Myxovirus resistance 
NF-κB Nuclear factor-kappa B 
ng Nanogram 
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NID Non-ionic detergent 
NIH National Institutes of Health 
nm Nanometer 
NPC Non parenchymal cell 
NP40 Nonidet P40 
OD Optical Density 
p- Phosphor- 
p53 Protein 53 or tumor protein 53 
PBS Phosphate buffered saline 
PCNA Prolifeating Cell Nuclear Antigen 
PCR Polymerase Chain Reaction 
PE Phycoerythrin 
PerCP Peridinin Chlorophll Protein 
PFA Paraformaldehyde 
pH Potential Hydrogenii 
PI Propidium iodide 
pIpC Polyriboinosinic-polyribocytidylic 
PMSF Phenylmethyl sulfonyl flurodie 
P/S Penicillin/streptomycin 
rev Reverse 
RNA Ribonucleic acid 
rpm Rounds per minute 
RT Room temperature 
RT-PCR Real-Time Polymerase Chain Reaction 
S Sense 
SD Standard deviation 
SDS PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
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SMA Smooth Muscle Actin 
STAT Signal Transducer and Activator of Transcription 
TAE Tris-acetat-EDTA 
Taq Thermus aquaticus 
TBS Tris buffered saline 
TBS-T Tris buffered saline supplemented with Tween 20 
TE Tris-EDTA 
TEMED N,N,N’,N’-Tetramethylethylendiamin 
TNF-α Tumornecrosis factor alpha 
TRIS Tris(hydroxymethyl)aminomethane 
TUNEL Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling 
U Unit 
UKA Universitatsklinikum Aachen 
v Volume 
vs. Versus 
w Week 
wt Weight 
WT Wild-type 
 
  
90 
Eidesstattliche erklärung 
Hiermit erkläre ich, Kunal Chaudhary, dass ich die Dissertation mit dem Titel: 
Differential Role of Caspase-8 in Hepatocytes and Non-Parenchymal Liver Cells in a 
Model of Chronic Liver Injury and Progenitor Cell Activation 
selbständig verfasst habe.  
 
Bei der Anfertigung wurden folgende Hilfen Dritter in Anspruch genommen: 
• In der Abteilung Gastroenterologie und Stoffwechselkrankheiten der medizinischen Klinik 
III im Universitätsklinikum Aachen habe ich die Versuche mit den im Kapitel „Material 
und Methoden“ aufgeführten Hilfen und Hilfsmitteln durchgeführt.  
• Die Anfertigung erfolgte unter der Leitung von P.D. Dr. med. Konrad Streetz, Abteilung 
Gastroenterologie und Stoffwechselkrankheiten der medizinischen Klinik III im 
Universitätsklinikum Aachen, die fachliche Betreuung wurde von Prof. Dipl. Ing. Dr. 
Werner Baumgartner Abteilung Zelluläre Neurobionik Institut für Biologie II der RWTH 
Aachen übernommen. 
  
Ich habe keine entgeltliche Hilfe von Vermittlungs- bzw. Beratungsdiensten in Anspruch 
genommen. Niemand hat von mir unmittelbar oder mittelbar entgeltliche Leistungen für 
Arbeiten erhalten, die im Zusammenhang mit dem Inhalt der vorgelegten Dissertation stehen. 
Die Synthesen der verwendeten Primer, Sonden und Antikörper wurden von den jeweils 
erwähnten Firmen durchgeführt 
 
Ich habe die Dissertation an folgenden Instituten angefertigt: 
Abteilung Gastroenterologie und Stoffwechselkrankheiten der medizinischen Klinik III im 
Universitätsklinikum Aachen 
Die Dissertation wurde bisher nicht für eine Prüfung oder Promotion oder für einen ähnlichen 
Zweck zur Beurteilung eingereicht. 
Ich versichere, dass ich die vorstehenden Angaben nach bestem Wissen vollständig und der 
Wahrheit entsprechend gemacht habe. 
 
___________________________________________ Aachen, 25 September 2012 
  
91 
Acknowledgment 
I thank all those people who supported me during my work which finally lead to successful 
accomplishment of this thesis. 
In first place I would like to thank PD. Dr. med Konrad Streetz, my direct supervisor who 
supported me from the beginning. Without his constant support during all my experiments 
and one to one discussions and evaluating my thesis as quickly as possible, it would not have 
been possible to finish the thesis successfully. It was my pleasure to work with him at the 
bench, side by side during the earlier phase of my thesis work. 
I sincerely thank Prof. Christian Trautwein, for supporting me and giving me the opportunity 
to work in his Department (Medical Clinic III) at the Medical University of Aachen. 
I sincerely thank and grateful to Prof. Dipl. Ing. Dr. Baumgartner for his support during the 
defence and for the examination of the thesis.  
I thank Prof. Dr. Wilhelm Jahnen-Dechent and Prof. Dr. Marcel Liauw for accepting me and 
being part of my Ph.D committee at RWTH and their support during the examination 
procedures. 
Thanks a lot to the entire animal care takers for their everyday work in the animal facility. 
Especially I would like to mention Frau Birgit Müller and Frau Roland for her exceptional 
performance. 
I would like to thank all my colleagues from Internal Medicine III, and particularly my co-
workers from the Streetz group who were a great help to me and who made coming to work a 
pleasure.  
I would like to thank Wei Hu, Stephanie Erschfeld, Arne Giebler, Michaela Kaldenbach and 
all those I forgot to mention, for all the good times I had during my work. 
Finally, I want to thank my family and my lovely wife Dr. Dessy Natalia for her patience, 
love, support, encouragement and endless understanding.  
  
92 
Publications 
Teile dieser Arbeit wurden bereits vorab veröffentlicht oder zur Publikation eingereicht: 
• Chaudhary, K., Liedtke, C., Trautwein, C., Streetz, K.L., Heterologous roles for 
caspase-8-signalling in hepatocytes and non-parenchymal cells in a model of liver stem 
cell activation and sclerosing cholangitis. Oral presentation at the International Liver 
CongressTM 2012 by EASL. April 2012. Barcelona, Spain. 
• Chaudhary, K., Liedtke, C., Trautwein, C., Streetz, K.L., Differential roles of caspase-8-
signalling in hepatocytes and non-parenchymal cells in a model of liver progenitor cell 
activation and sclerosing cholangitis, The Liver Congress 2011 by AASLD, Nov. 2011, 
Hepatology, 54 (4), p.959a, 2011. San Francisco, USA. 
• Chaudhary, K., Liedtke, C., Trautwein, C., Streetz, K.L., Hepatocyte protection by 
conditional caspase8-deletion hampers activation of the liver progenitor cell compartment 
in a model of sclerosing cholangitis, The Liver Congress 2010 by AASLD, Oct.-Nov. 
2010, Hepatology, 52 (4), p.967a, 2010. Boston, USA. 
 
 
 
  
93 
Lebenslauf 
Name: Kunal Chaudhary 
Geburtsdatum:  25.09.1979 
Geburtsort: Kota, Indien 
Familienstand:  Verheiratet 
 
Schulausbildung: 
 
1996-1998 
Higher Secondary School, Gujarat, Indien 
 
Studium: 
 
1998-2002 
Bachelor of Science (B.Sc) 
Navinchandra Mafatlal College of Agril. Sciences, Gujarat, Indien 
 2003-2006 
Master of Science (M.Sc) 
Georg-August Universität. Göttingen, Deutschland 
 2006-2007 
Master of Science (M.Sc) 
Gent Universität, Gent, Belgien 
 
Wissenschaftliche 
Tätigkeit: 
 
2008-2008 
Wissenschaftlicher Assistent  
Deutsch Primatenzentrum (DPZ GmbH), Leibniz Institut für 
Primatenforschung, Göttingen, Deutschland 
 2008-2009 
Wissenschaftlicher Assistent  
Cardiovascular Research Institute Maastricht, Universitätsklinik 
Maastricht, Niederlande 
 2009-2012 
Doktorand 
Forschunglabor der Medizinischen Klinik III in der Arbeitsgruppe 
von PD. Dr. med. Konrad Streetz 
Universitätsklinikum Aachen, RWTH Aachen, Deutschland 
 
